<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/74299423-0E5D-4739-A3AA-B17137135C9B"><gtr:id>74299423-0E5D-4739-A3AA-B17137135C9B</gtr:id><gtr:name>Linkoping  University</gtr:name><gtr:address><gtr:line1>Linkoping</gtr:line1><gtr:postCode>SE-581 83</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1FADA516-503F-4D04-96FD-28248BF7B77E"><gtr:id>1FADA516-503F-4D04-96FD-28248BF7B77E</gtr:id><gtr:name>The Binding Site</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4E777F7E-8B7E-406A-87FB-39A7026F891F"><gtr:id>4E777F7E-8B7E-406A-87FB-39A7026F891F</gtr:id><gtr:name>Uppsala University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52423922-8331-4312-A996-E4734BB4D688"><gtr:id>52423922-8331-4312-A996-E4734BB4D688</gtr:id><gtr:name>Utrecht University</gtr:name><gtr:address><gtr:line1>PO Box 80125</gtr:line1><gtr:line2>3508 TC Utrecht</gtr:line2><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/74299423-0E5D-4739-A3AA-B17137135C9B"><gtr:id>74299423-0E5D-4739-A3AA-B17137135C9B</gtr:id><gtr:name>Linkoping  University</gtr:name><gtr:address><gtr:line1>Linkoping</gtr:line1><gtr:postCode>SE-581 83</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E65D5505-6DF9-4801-9019-B9EDE5D0EE5D"><gtr:id>E65D5505-6DF9-4801-9019-B9EDE5D0EE5D</gtr:id><gtr:name>University Medical Center Gronigen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1FADA516-503F-4D04-96FD-28248BF7B77E"><gtr:id>1FADA516-503F-4D04-96FD-28248BF7B77E</gtr:id><gtr:name>The Binding Site</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F11355FE-3223-4085-978D-009A4F86761A"><gtr:id>F11355FE-3223-4085-978D-009A4F86761A</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>Nigel</gtr:otherNames><gtr:surname>Hawkins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/72A324FF-B975-443D-BDD8-19E9649401E7"><gtr:id>72A324FF-B975-443D-BDD8-19E9649401E7</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:otherNames>Brian</gtr:otherNames><gtr:surname>Pepys</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G7900510"><gtr:id>FA4479B9-FFED-4BD0-9294-CA32EEAC4047</gtr:id><gtr:title>Pentraxins and amyloidosis: from molecular mechanisms to medicines</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G7900510</gtr:grantReference><gtr:abstractText>We have invented a platform technology for creation of drugs to target any blood protein that causes disease and are using it to develop new medicines.&amp;nbsp; Our most advanced drug compound targets serum amyloid P component (SAP) and is undergoing clinical testing in amyloidosis, Alzheimer?s disease and osteoarthritis.&amp;nbsp; It may also be useful in type 2, maturity onset, diabetes.&amp;nbsp; Other drugs are being designed to treat and prevent hitherto untreatable lethal forms of inherited and acquired amyloidosis.&amp;nbsp; Our drug which targets C?reactive protein (CRP) is beneficial in rat models of heart attack and stroke, and will be developed for clinical trials.
&amp;nbsp;
The MRC has funded, continuously since 1979, our research on CRP and SAP, which are related human blood proteins, and our work on amyloidosis, a usually fatal disease. &amp;nbsp;We study the individual proteins, their interactions with each other and with cells, and animal models of human disease, and we also perform clinical testing in patients.
&amp;nbsp;
We have introduced new methods of diagnosis and treatment that improve quality and duration of life for most patients who attend the world leading NHS National Amyloidosis Centre in our Department.&amp;nbsp; We will continue to refine and develop these methods.</gtr:abstractText><gtr:technicalSummary>We have elucidated much of the molecular pathogenesis, natural history and response to treatment of amyloidosis, as well as the structures and functions of the pentraxins and their roles in disease, but effective therapies are still urgently required. Our discoveries have enabled us to develop a powerful new drug, CPHPC, with a novel pharmacological mechanism of action that both inhibits ligand binding by serum amyloid P component (SAP) and depletes it from the circulation. Clinical testing of CPHPC in amyloidosis is providing promising results, has revealed an unexpected possible application in osteoarthritis, and has informed our rational design of other new drug compounds to target C-reactive protein (CRP) and amyloid fibril precursor proteins. We now aim:
1] to implement this translational research to create new medicines and treatments, including: the continued evaluation and development of CPHPC in systemic amyloidosis; clinical evaluation of CPHPC in Alzheimer?s disease and osteoarthritis; proof of principle demonstration that inhibitors of CRP binding abrogate the tissue damaging effects of human CRP in vivo, opening the way to development of cardioprotective and neuroprotective drugs for clinical use; and continued design, synthesis and experimental evaluation of our novel compounds targeting amyloid fibril precursor proteins, successful outcomes of which will lead swiftly to their clinical development.
2] to continue exploring the roles of pentraxins in health and disease, including: the role of human CRP in experimental murine atherosclerosis and atherothrombosis in vivo, and in human foam cell formation and tissue factor production in vitro; further epidemiological studies of CRP in cardiovascular disease; the role of SAP in the islet amyloid and clinical expression of experimental murine type 2 diabetes; the role of human SAP in the normal glomerular basement membrane and in host defence against Shiga toxins.
3] to vigorously pursue our collaborative studies of the structures of CRP, SAP and their complexes with low molecular weight ligands, peptides, proteins and amyloid fibrils that invaluably subtend all our work on drug design and development as well as providing critical fundamental knowledge of these important molecules.
4] to sustain our very productive and wide ranging clinical research programme on the causes, pathogenesis, diagnosis and treatment of human amyloidosis and the hereditary periodic fever syndromes.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1979-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>9935455</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Investigation of CRP-ligand interactions by NMR</gtr:description><gtr:id>BB367154-1402-4CD9-A82A-74F903B55F58</gtr:id><gtr:impact>N/a as still very early</gtr:impact><gtr:outcomeId>pbv1Lrrp1u1-1</gtr:outcomeId><gtr:partnerContribution>The partner and his group will undertake these high resolution NMR studies using our materials in order to gain new insights into the factors controlling CRP-ligand and CRP-CRP interactions.</gtr:partnerContribution><gtr:piContribution>Our work has centred on the development of palindrominic ligands as inhibitors of CRP binding to damaged and dead cells in order to prevent the exacerbation of CRP-mediated complement activation and subsequent tissue injury. We have prepared highly purified endotoxin free human CRP together with our patented CRP-crosslinking palindromic ligands for NMR analysis. This is part of our ongoing programme of rational design of novel CRP inhibitors.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Kennedy Institute of Rheumatology</gtr:department><gtr:description>CRP is not immunomodulatory in vivo (Prof Marina Botto)</gtr:description><gtr:id>0027074B-986A-4C60-AC72-158EF558C716</gtr:id><gtr:impact>Publication: Carlucci, F., Cook, H.T., Garg, A., Pepys, M.B. and Botto, M. (2009) Single injection of human C-reactive protein has no effect on murine lupus or nephrotoxic nephritis. Arth. Rheum. (in press).</gtr:impact><gtr:outcomeId>6FC5EBE34FE-1</gtr:outcomeId><gtr:partnerContribution>Synergistic collaboration enabled us to demonstrate that published reports of potent in vivo immunomodulation by human C-reactive protein were not reproducible. The Botto team are expert in the relevant animal models.</gtr:partnerContribution><gtr:piContribution>We provided world leading expertise in all aspects of CRP, including provision of highly purified authentic functionally fully active protein, as well as contributing to experimental design and writing the paper.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Uppsala University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>EURAMY collaboration (Prof Per Westermark and others)</gtr:description><gtr:id>4A4AEA13-92BC-4923-A11D-9B013540D205</gtr:id><gtr:impact>Improved collaboration with virtually all prominent groups working within the field of amyloidosis in Europe</gtr:impact><gtr:outcomeId>DC5624C11E0-1</gtr:outcomeId><gtr:partnerContribution>Improved collaboration with virtually all prominent groups working within the field of amyloidosis in Europe</gtr:partnerContribution><gtr:piContribution>This is an EU FP6 funded collaboration of 17 amyloidosis groups accross the EU. Major contribution to experimental and clinical studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cardiff University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine</gtr:department><gtr:description>CRP CFH interaction (Prof Paul Morgan)</gtr:description><gtr:id>0AA67E3B-BFE6-44DA-ABA0-C56FC3E4857A</gtr:id><gtr:impact>18786923.</gtr:impact><gtr:outcomeId>B008CC3C0DD-1</gtr:outcomeId><gtr:partnerContribution>Morgan and his team provided expertise, reagents and experiments for a very productive collaboration leading to novel and important results.</gtr:partnerContribution><gtr:piContribution>We provided expertise, reagents and experiments for a very productive collaboration leading to novel and important results. We showed that human CRP is bound by CFH only when the CRP is denatured, with important implications for speculation about the possible pathogenic role of these proteins in AMD.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Gronigen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Quantification and treatment of amyloidosis (Dr Bouke Hazenberg)</gtr:description><gtr:id>1E85CB3F-C43F-47FB-9599-FB0D286C8626</gtr:id><gtr:impact>16564782, 17554116, 17577686.</gtr:impact><gtr:outcomeId>983B9430671-1</gtr:outcomeId><gtr:partnerContribution>Publications on improved methods for quantifying and treating amyloidosis.</gtr:partnerContribution><gtr:piContribution>Methodology and collaborative clinical study of patients.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Depletion of SAP in Alzheimer's disease by CPHPC (Prof Martin Rossor)</gtr:description><gtr:id>72F9DC9C-0F98-4709-B931-8809B0FCBAA9</gtr:id><gtr:impact>19372378.</gtr:impact><gtr:outcomeId>FC0CFD06DD6-1</gtr:outcomeId><gtr:partnerContribution>The positive findings of our exploratory clinical study provide compelling support for proceeding to a large randomised controlled trial of CPHPC in Alzheimer's disease.</gtr:partnerContribution><gtr:piContribution>Development of CPHPC as an SAP depleting drug from conception to human studies in amyloidosis. We contributed substantially to the design and analysis of this first clinical study of CPHPC in patients with Alzheimer's disease.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Clinical Pharmacology &amp; Therapeutics</gtr:department><gtr:description>Genetic studies of CRP and factor H (Prof Aroon Hingorani)</gtr:description><gtr:id>989010F2-9B79-4949-BE17-D13B08AA42DF</gtr:id><gtr:impact>We developed a high throughput automated immunoassay for complement factor H (CFH) enabling the Hingorani lab to assat CFH in large scale epidemiological series of CHD and AMD patients. These important methods and results are currently being prepared for publication.</gtr:impact><gtr:outcomeId>33F1A3C03EC-1</gtr:outcomeId><gtr:partnerContribution>Collaborative exchange of ideas, samples sets and information leading to new knowledge in the field.</gtr:partnerContribution><gtr:piContribution>We provide our world leading knowledge, experience and expertise in all aspects of C-reactive protein, and our expertise in complement and plasma protein immunoassay.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Macrophage biology</gtr:description><gtr:id>5EF793A5-AFD5-4830-B736-096257D8465C</gtr:id><gtr:impact>Collaborative research paper ready for submission.</gtr:impact><gtr:outcomeId>545cd7f6666143.90121557-1</gtr:outcomeId><gtr:partnerContribution>Analyses in vitro of the properties of monocytes and multinucleated giant cells.</gtr:partnerContribution><gtr:piContribution>Histology, immunocytochemistry and electron microscopy analyses of in vivo anti-SAP therapy experiments in mice.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Cognitive Function and Ageing Study (CFAS)</gtr:department><gtr:description>Brain SAP content and cognition in the elderly at death</gtr:description><gtr:id>12603659-AA99-4F4E-BB1F-870C29E16583</gtr:id><gtr:impact>The study is just starting.</gtr:impact><gtr:outcomeId>iL6DCKbiRyR-1</gtr:outcomeId><gtr:partnerContribution>The MRC CFAS Tissue Resource is unique and uniquely able to provide the large number of samples required for this study.</gtr:partnerContribution><gtr:piContribution>Pepys is investigating the role of human serum amyloid P component (SAP) in neurodegeneration and seeks a relationship between the presence, distribution and amount of SAP in different brain regions of elderly individuals whose cognitive status at the time fo death is well established. Pepys has world leading expertise in all aspects of the study of SAP.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Binding Site</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Development of serum free light chain assays in amyloidosis (Prof Arthur Bradwell)</gtr:description><gtr:id>C5AD5607-F5B2-470C-9367-30F621B5156C</gtr:id><gtr:impact>Widespread adoption throughout the world of the serum free light chain assay in the diagnosis and management of AL amyloidosis. 16822290, 18708629.</gtr:impact><gtr:outcomeId>CC91241B725-2</gtr:outcomeId><gtr:partnerContribution>Publications.</gtr:partnerContribution><gtr:piContribution>Clinical studies to determine the utility of serum free light chain measurements in the diagnosis and management of AL amyloidosis.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Neuroscience, Physiology &amp; Pharmacology</gtr:department><gtr:description>SAP neurotoxicity (Dr Frances Edwards, Prof Sebastian Brandner)</gtr:description><gtr:id>E1EC5286-21CE-44C4-9B86-E661A18815D3</gtr:id><gtr:impact>Award of MRC research grant &amp;quot;Neurotoxicity of human serum amyloid P component&amp;quot; to Edwards, Brandner, Dr Paul Simons (a member of the Pepys group) and Pepys in Jan 2012</gtr:impact><gtr:outcomeId>RAsM7VLNrLZ-1</gtr:outcomeId><gtr:partnerContribution>Edwards is a neuroscientist, specialised in CNS electrophysiology for study of fast synaptic transmission. She and her collaborators pioneered the application of patch clamp techniques to brain slices. In recent years she has optimised methods
for detailed characterisation of plasticity and structure of individual synapses in acute and organotypic brain slices. Brandner is the Head of Neuropathology at the UCL Institute of Neurology and one of the world's leading experts on murine neuropathology.</gtr:partnerContribution><gtr:piContribution>The objectives of the work are to:
1. Characterise the toxic effects of human serum amyloid P component (SAP) on cerebral neurones in organotypic
hippocampal slices in vitro with respect to time and dose dependence of abnormalities in synaptic transmission, paired pulse ratio, long term potentiation, necrotic and apoptotic neuronal cell death, binding and entry of SAP in cells and nuclear localisation.
2. Establish that the adverse effects of human SAP are specific, by comparison with the very closely related human C reactive protein and SAP from mice rats and mice, and demonstrate abrogation of human SAP toxicity by CPHPC, our specific SAP binding and inhibitory drug.
3. Investigate the time and dose dependence of abnormalities of synaptic transmission in the brains of human SAP transgenic mice, characterise these abnormalities precisely and identify and characterise any associated neuropathological changes in the brain in comparison with age and sex matched wild type litter mate controls.
4. Investigate cognitive performance of human SAP transgenic mice in comparison with age and sex matched wild type littermate controls in relation to age and level of human SAP expression in different strains.
5. Investigate effects of human SAP expression in TASTPM mice, which carry variant human PS1 and APP transgenes associated with hereditary Alzheimer's disease. In particular we will seek modulation by human SAP of the time of onset and severity of abnormalities of synaptic transmission, cognition and neuropathology.
6. Investigate the capacity of sustained depletion of human SAP, produced by life long treatment with CPHPC, to abrogate any or all of the neurological abnormalities observed in human SAP transgenic mice.
Human SAP likely contributes to formation and persistence of cerebral amyloid deposits and neurofibrillary tangles, and is therefore already an attractive therapeutic target in AD. The results of the present work will compellingly strengthen the case for clinical trials of CPHPC and SAP depletion in AD and possibly also other neurodegenerative causes of cognitive loss. 
Pepys has worked on SAP since 1974, supported throughout by the MRC, and with his collaborators has contributed most of what is known about this protein in humans and other species. He discovered the role of SAP in amyloidosis, validated it as a therapeutic target and developed CPHPC with Roche.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>CPHPC and anti SAP antibody collaboration with GSK</gtr:description><gtr:id>BFD19747-D41E-44C0-82AE-B5D8D8C12524</gtr:id><gtr:impact>A full scale clinical development programme is in progress in which GSK are progressing our small molecule drug, CPHPC, and have already humanised our mouse monoclonal antibodies to human serum amyloid P component. We continue, now without MRC support, to conduct the essential experimental component of the programme. A Phase 1, Open Label, Dose Characteristic Study to Investigate the pharmacokinetics, pharmacodynamics, safety, and tolerability of Intravenous and subcutaneous doses of CPHPC in patients with systemic amyloidosis was conducted by GSK in 2012 enabling progression to a single dose first in human study of anti-SAP antibodies co-administered with CPHPC in patients with systemic amyloidosis. This started in Q3 2013 and is providing very encouraging results which are currently being written up for publication. GSK have recognised achievement of Clinical Proof of Mechanism and have accordingly paid a substantial milestone payment to Pentraxin Therapeutics Ltd. The European Medicines Agency have awarded Orphan Drug Status to the potential product and furthermore have adopted it as their flagship candidate for adaptive licensing. The original patent applications, licensed to GSK for this programme, have been granted and GSK have filed new patents as the work proceeds.</gtr:impact><gtr:outcomeId>773145C8325-1</gtr:outcomeId><gtr:partnerContribution>GSK have fully humanised our mouse optimal monoclonal antibody, conducted animal toxicology with it in mice treated with our small molecule drug CPHPC and conducted phase I studies of CPHPC in healthy volunteers and patients with systemic amyloidosis. The entirely favourable results have enabled progression to a phase I study of the obligate therapeutic partnership of CPHPC and anti-SAP antibody in amyloidosis patients, which is now giving favourable results. All this development work is absolutely dependent on very close and continuous interactions between the unique expertise of our group and that of GSK.</gtr:partnerContribution><gtr:piContribution>We have invented a new treatment for systemic amyloidosis and licensed the relevant IP and proprietary knowledge to GSK for full scale clinical development to be conducted in collaboration with our team, each party contributing their particular expertise and resource in a synergistic programme aimed at the earliest possible clinical testing and commercial development.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Linkoping University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Islet amyloid and type 2 diabetes (Dr Gunilla Westermark)</gtr:description><gtr:id>BA52DC89-7000-421B-BCDC-44539D605367</gtr:id><gtr:impact>SAP is always present in the islet amyloid of human type 2 diabetes. A key positive finding in our long term collaborative study, with Dr Gunilla Westermark, of islet amyloid and type 2 diabetes in ob/ob mice expressing transgenic human IAPP with either mouse SAP deficiency or transgenic human SAP expression, is the presence of human SAP in the islet amyloid. This validates the model for testing our potent new approach to clearance of established amyloid in vivo using CPHPC plus anti SAP antibody.</gtr:impact><gtr:outcomeId>8B3FBB36BBF-1</gtr:outcomeId><gtr:partnerContribution>Westermark has created ob/ob mice expressing transgenic human IAPP which develop both clinical type 2 diabetes and islet amyloid deposits. These are ideal models for study of the role of SAP in islet amyloidosis and type 2 diabetes and especially the possible utility of such SAP as a therapeutic target for the new approaches to treatment of amyloid that we have invented.</gtr:partnerContribution><gtr:piContribution>We have shown that in human SAP transgenic mice, the human protein localises to islet amyloid deposits just as it does in man, and is therefore a valid target for treatment with our new invention for clearance of systemic amyloid deposits that is being developed with GSK. We will use our reagents to determine whether this treatment clears islet amyloid in the Westermark mice and affects their clinical diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Laboratory of Molecular Biology (LMB)</gtr:department><gtr:description>Monoclonal light chain structure (Sir Gregory Winter)</gtr:description><gtr:id>20BBD5C1-9E36-4830-AE46-D57DD5CB0F58</gtr:id><gtr:impact>17292396</gtr:impact><gtr:outcomeId>1061CE4F5F9-1</gtr:outcomeId><gtr:partnerContribution>The Winter lab undertook studies of an interesting amyloid-like light chain aggregate that they had identified.</gtr:partnerContribution><gtr:piContribution>We providced amyloid expertise to show that although the aggregates had a vey intersting structure they were not in fact genuine amyloid fibrils</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Utrecht University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Islet amyloid and type 2 diabetes (Dr Jo Hoeppener)</gtr:description><gtr:id>A9A2BE05-8B5B-43B0-A613-0AC5ED5A6EB2</gtr:id><gtr:impact>SAP is always present in the islet amyloid of human type 2 diabetes. A key positive finding in our long term collaborative study, with Dr Jo Hoeppener, of islet amyloid and type 2 diabetes in ob/ob mice expressing transgenic human IAPP with either mouse SAP deficiency or transgenic human SAP expression, is the presence of human SAP in the islet amyloid. This validates the model for testing our potent new approach to clearance of established amyloid in vivo using CPHPC plus anti SAP antibody.</gtr:impact><gtr:outcomeId>BF913605F8E-1</gtr:outcomeId><gtr:partnerContribution>Hoeppener has created ob/ob mice expressing transgenic human IAPP which develop both clinical type 2 diabetes and islet amyloid deposits. These are ideal models for study of the role of SAP in islet amyloidosis and type 2 diabetes and especially the possible utility of such SAP as a therapeutic target for the new approaches to treatment of amyloid that we have invented.</gtr:partnerContribution><gtr:piContribution>We have shown that in human SAP transgenic mice, the human protein localises to islet amyloid deposits just as it does in man, and is therefore a valid target for treatment with our new invention for clearance of systemic amyloid deposits that is being developed with GSK. We will use our reagents to determine whether this treatment clears islet amyloid in the Hoeppener mice and affects their clinical diabetes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC UK Brain Banks Network</gtr:department><gtr:description>SAP in normal human brain</gtr:description><gtr:id>E60F703E-FEAE-484C-BCB3-E1793BE895AD</gtr:id><gtr:impact>The project has just started</gtr:impact><gtr:outcomeId>DqrpA8bwQmL-1</gtr:outcomeId><gtr:partnerContribution>The MRC Brain Bank is a unique resource, uniquely able to supply the material required for this study.</gtr:partnerContribution><gtr:piContribution>Pepys is investigating the role of human serum amyloid P component (SAP) in neurodegeneration and is characterising the presence, distribution and amount of SAP in different brain regions of individuals dying over the whole age range represented in the Brain Bank. Pepys has world leading expertise in all aspects of the study of SAP.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Molecular and Clinical Medicine Edinburgh</gtr:department><gtr:description>Exclusion of role for prions in systemic amyloidosis (Prof Ironside)</gtr:description><gtr:id>BF5B97A1-B43A-487D-854E-9345E3C0078D</gtr:id><gtr:impact>17955450.</gtr:impact><gtr:outcomeId>7B502ACBA03-1</gtr:outcomeId><gtr:partnerContribution>Publication.</gtr:partnerContribution><gtr:piContribution>A collaborative study that excluded involvement of prions in the pathogenesis of systemic amyloidosis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Clinical Medicine</gtr:department><gtr:description>DNA Vaccination (Prof Thomas Hanke)</gtr:description><gtr:id>5B9397DF-8896-4AB5-9BBF-A811BAF9E044</gtr:id><gtr:impact>MRC DCS award to fund the study which covers the disciplines of immunology and drug development.</gtr:impact><gtr:outcomeId>WxqZwUX4JEa-1</gtr:outcomeId><gtr:partnerContribution>Hanke and the Oxford team have a long track record in designing novel vaccine immunogens and vaccination regimens. They have great expertise in translational studies, comprising eleven studies involving candidate HIV-1 vaccines over the past 10 years (reviewed in ref 38 and unpublished), coupled with high level specialist expertise in measuring and characterizing vaccine-induced T cells. They are providing the unique GMP DNA vaccine for this study.</gtr:partnerContribution><gtr:piContribution>The goal of the project is to demonstrate that DNA vaccination of normal human volunteers in whom circulating human serum amyloid P component (SAP) has been depleted by the drug, (R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxohexanoyl] pyrrolidine-2-carboxylic acid (CPHPC), induces an enhanced immune response compared to the same vaccination in control subjects with normal circulating SAP values. The vaccine to be used is directed at conserved epitopes of the HIV-1 virus. The objectives are:
1. Demonstrate that the T cell immune response to the three priming doses of DNA vaccine is significantly enhanced in SAP depleted subjects compared to identically vaccinated SAP sufficient control subjects.
2. Demonstrate that the T cell immune response to subsequent boosting by the cognate protein antigen, is significantly enhanced in subjects who were primed by DNA vaccination whilst SAP depleted, compared to identically vaccinated SAP sufficient control subjects.
3. Determine whether the enhanced T cell responses which may be observed after SAP depletion are more potent than the responses in controls in suppressing HIV-1 virus replication in vitro, and thus, (a) support the general concept that SAP depletion can be used to enhance the protective immunity inducible by DNA vaccination in humans, and (b) encourage further vaccination studies against conserved regions of HIV-1 in order to develop an effective protective and potentially
therapeutic vaccine against this pathogen.
The study will also confirm safety and tolerability of 3 courses of 24 h intravenous infusion of CPHPC, to produce maximal depletion of plasma SAP, immediately before intramuscular injection of DNA vaccine.
Prof Sir Mark Pepys developed the drug CPHPC which uniquely depletes circulating SAP to extremely low concentrations and he originated the concept for the present trial. He is the inventor on the key patents covering CPHPC which are owned by his UCL spin out company. Some of the patents are licensed to GSK and they have helpfully provided the drug for the present study.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medical and Dental Sciences</gtr:department><gtr:description>Development of serum free light chain assays in amyloidosis (Prof Arthur Bradwell)</gtr:description><gtr:id>05FDADBF-7ECF-4F56-93E3-4973EE3070E2</gtr:id><gtr:impact>Widespread adoption throughout the world of the serum free light chain assay in the diagnosis and management of AL amyloidosis. 16822290, 18708629.</gtr:impact><gtr:outcomeId>CC91241B725-1</gtr:outcomeId><gtr:partnerContribution>Publications.</gtr:partnerContribution><gtr:piContribution>Clinical studies to determine the utility of serum free light chain measurements in the diagnosis and management of AL amyloidosis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Development of transthyretin superstabilisers</gtr:description><gtr:id>242EB45C-0CD5-4A4C-932F-97875D2D8399</gtr:id><gtr:impact>The development programme is still at an early stage. Novel transthyretin stabilising compounds have been identified. These are being evaluated and refined for eventual clinical testing. New Intellectual Property has arisen and is being protected appropriately.</gtr:impact><gtr:outcomeId>Tzv81G8iiWd-1</gtr:outcomeId><gtr:partnerContribution>GlaxoSmithkline are providing medicinal chemistry, drug development and Intellectual Property expertise and practical support to the programme. They are designing and synthesising novel compounds, are running a full, early stage, drug development programme and are preparing to file a patent to protect arising IP.</gtr:partnerContribution><gtr:piContribution>Transthyretin is an inherently amyloidogenic protein and forms microscopic amyloid deposits in all individuals over the age of 80 years. In some aged individuals massive transthyretin amyloid deposition in the heart causes fatal senile cardiac amyloidosis, a condition which is rarely diagnosed but is almost certainly much more prevalent than currently recognised. Most of the &amp;gt;100 rare mutations in the human transthyretin gene increase the amyloidogenicity of the respective variant proteins and cause autosomal dominant adult onset hereditary transthyretin amyloidosis, usually presenting as familial amyloid polyneuropathy. There is currently no effective treatment for this uniformly fatal disease. Since transthyretin amyloidogenesis involves misfolding and dissociation of the native tetrameric structure of the protein, a rational therapeutic approach is the use of small molecule ligands which are specifically bound by transthyretin and stabilise its native structure and assembly. Prof Sir Mark Pepys and his research group are world leaders in the study of transthyretin misfolding and amyloid fibrillogenesis. They contribute both intellectually and practically to the design and evaluation of novel TTR stabilising ligands.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Medicine</gtr:department><gtr:description>Structures of CRP and SAP (Prof Steve Wood)</gtr:description><gtr:id>5A0466B4-DC0C-4D31-8A99-E34AF3A5194E</gtr:id><gtr:impact>The outstanding structural biology studies of Professor Steve Wood and his team have been essential for our successful work on pentraxins and drug design, and enabled their recruitment to UCL, with two tenured chairs (Wood, Jon Cooper), one senior lecturer post (Alun Coker) and 6 others on soft money. A new Laboratory of Protein Crystallography led by Wood has been established in the Centre for Amyloidosis and Acute Phase Proteins and has greatly increased the speed and efficiency of our extensive collaboration. This critical development was made possible by generous MRC support throughout the 20 years that Wood and I have collaborated. In the present quinquennium they have solved 18 crystal structures of human and animal pentraxins and their ligand complexes, elucidating protein structure and function and indispensably aiding drug design.</gtr:impact><gtr:outcomeId>C5E02388156-1</gtr:outcomeId><gtr:partnerContribution>The more than 25 years of close and highly productive collaboration with the powerful structural biology expertise of Steve Wood and his colleagues has underpinned a large part of our world leading discoveries and inventions in the field of pentraxins and amyloid proteins.</gtr:partnerContribution><gtr:piContribution>We have provided the isolated, purified and highly characterised proteins that Wood and his team have crystallised for X-ray analysis and other structural studies. Together we have designed and developed small molecule ligands for these proteins which are now in development as drugs. We have held and have under consideration many grants which have brought very substantial sums of money to support our collaborative work but your rigid form does not allow us to enter this information!</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Public Health and Primary Care</gtr:department><gtr:description>Epidemiological studies of CRP in CHD (Prof John Danesh)</gtr:description><gtr:id>E2892776-9A56-4B8E-9A01-0958AD703392</gtr:id><gtr:impact>The compelling results of the Emerging Risk Factors Collaboration (ERFC) observational study with 126,338 subjects and 23,587 first-ever incident vascular disease outcomes or nonvascular deaths during 1.1 million person-years of follow-up are published online in the Lancet on 22 Dec 2009. The largest ever Mendelian randomisation epidemiology study of CRP and CVD was published in BMJ in 2011. The defnitive observational study of all available data on CRP and CHD was published in the New England Journal of Medicine in 2012.</gtr:impact><gtr:outcomeId>802F263F6F8-1</gtr:outcomeId><gtr:partnerContribution>The combination of our world leading knowledge, experience and expertise in all aspects of C-reactive protein with the exceptional epidemiological skills deployed by Professor John Danesh, his team and his huge international set of collaborators, especially under the umbrella of the Emerging Risk Factors Collaboration (ERFC) that he established and directs, is making a unique contribution to knowledge in cardiovascular disease and more widely.</gtr:partnerContribution><gtr:piContribution>We provide our world leading knowledge, experience and expertise in all aspects of C-reactive protein to the design, conduct and reporting of the collaborative studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Development of canakinumab as a treatment for CAPS (Dr Thomas Jung)</gtr:description><gtr:id>3D92C30E-813D-475F-8380-F0036631E55E</gtr:id><gtr:impact>Launching of canakinumab as a highly effective treatment for CAPS in the EU in 2009. 19364880, 19494217.</gtr:impact><gtr:outcomeId>D6CF033BFEA-1</gtr:outcomeId><gtr:partnerContribution>Publications.</gtr:partnerContribution><gtr:piContribution>Design and execution of clinical and in vitro studies of canakinumab, a human monoclonal anti-IL-1 antibody, in patients with cryopyrin associated periodic fever syndrome.</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BBC and many other national and international radio interviews</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E27CF412-2F4C-40C6-A470-52EE0EC69F1B</gtr:id><gtr:impact>Interviews on BBC Today programme &amp;amp; other multiple national and international radio shows, regarding various high impact publications of our work on drug development for amyloidosis, Alzheimer's disease and cardiovascular disease in Nature, PNAS, etc. Also in relation to my Harveian Oration at the RCP in 2007.

Much public interest, especially from potential patients and some investors.</gtr:impact><gtr:outcomeId>124B7EDC586</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Articles in The Times and The Financial Times</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0BC437C5-3ADE-4D72-AF05-AD80C66D2AF0</gtr:id><gtr:impact>Articles published in The Times and The Financial Times - outcome was greater public awareness of amyloidosis and Prof Mark Pepys's research to develop treatments for it

Publications were very recent</gtr:impact><gtr:outcomeId>HoMZkiz5iS7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://pentraxin.wordpress.com/news/</gtr:url><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>201353</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Strategic Skills Award</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K000187/1</gtr:fundingRef><gtr:id>D8E60723-78ED-4A96-8018-A0357D478387</gtr:id><gtr:outcomeId>sSwUmbwGApj0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>677715</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British Heart Foundation</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>CD649196-73A1-43AF-B1EE-D74C572016A9</gtr:id><gtr:outcomeId>aq3CyRQ7AKP</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2571000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Strategic Award via UCLH/UCL BRC</gtr:description><gtr:end>2019-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>47275A5A-A892-4E44-A684-6C83E7CF3DDA</gtr:id><gtr:outcomeId>5460b11bb304e1.20927674</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>377634</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3R's Project Grant</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>AC9F3F16-5179-4376-917C-8FB95A240AC3</gtr:id><gtr:outcomeId>E483F14B89C0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>900000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>UCL/ UCLH BRC</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>205048D8-A9C1-4F9F-B473-A9A3B3C6A98C</gtr:id><gtr:outcomeId>si7eyyPDwPk</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>UCL/ UCLH BRC</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>A5A7ECB3-470D-4325-8865-B024D54146BB</gtr:id><gtr:outcomeId>CQnV1HpsGR6</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3891205</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Seeding Drug Discovery Strategic Award</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>01BC3AF1-325A-47A7-9B1A-D28910347655</gtr:id><gtr:outcomeId>64433B267460</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1034631</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Biomarkers Grant</gtr:description><gtr:end>2010-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A7E3CFD5-AAE7-43B0-8A4A-EA6DC0A58B75</gtr:id><gtr:outcomeId>C344CD925C30</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Use of a non-proteinaceous agent for the preparation of a composition for the treatment of a subject having a disorder caused by a pathogenic protein, by therapeutic depletion of the pathogenic protein from the plasma of the subject; wherein the treatment comprises administering to the subject a dosage of the agent sufficient for therapeutic depletion; wherein the agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of the proteins in the presence thereof; and wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>A1A24586-2588-4A5F-B836-57160309EFFB</gtr:id><gtr:impact>Therapy in development.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>rtZitec3bWX</gtr:outcomeId><gtr:patentId>US7691897</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Therapeutic agent</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of a compound which depletes serum amyloid P component from the circulation, in combination with an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>59BE3892-8442-488D-B9D0-A84C3E976925</gtr:id><gtr:impact>Potential therapy in development in collaboration with GlaxoSmithKline.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58b69a1dc9ee89.26680010</gtr:outcomeId><gtr:patentId>MX342991</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Combinations of SAP depleting agents and anti-SAP antibodies</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Agent for the depletion of an unwanted protein population from the plasma of a subject, which agent comprises a plurality of ligands covalently co-linked so as to from a complex with a plurality of the proteins in the presence thereof, wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins, wherein the agent is a non-proteinaceous agent other than a D-proline of the formula (I-A) or (I-B) wherein R is formula (a) the group; R&amp;lt;1&amp;gt; is hydrogen or halogen; X is -(CH2)N-; -CH(R&amp;lt;2&amp;gt;)(CH2)n-; -CH2O(CH2)n-; -CH2NH-; benzyl, -C(R&amp;lt;2&amp;gt;)=CH-; -CH2CH(OH)-; or thiazol-2,5-diyl; Y is -S-S; -(CH2)n-; -O-; -NH-; -N(R&amp;lt;2&amp;gt;)-; -CH=CH; - NHC(O)NH-; - N(R&amp;lt;2&amp;gt;)C(O)N(R&amp;lt;2&amp;gt;)-; -N[CH2C6H3(OCH3)2]-; -N(CH2C6H5)-; -N(CH2C6H5)C(O)N(CH2C6H5)-; -N(alkoxyalkyl)-; N(cycloalkyl-menthyl)-; 2,6-pyridyl; 2,5-furanyl; 2,5-thienyl; 1,2-cyclohexyl; 1,3-cyclohexyl; 1,4-cyclohexyl; 1,2-naphthyl; 1,4-naphtyl; 1,5-naphthyl; 1,6-naphthyl; biphenylen; or 1,2-phenylen, 1,3-phenylen and 1,4-phenylen, wherein the phenylen groups are optionally substituted by 1-4 substituents, selected from halogen, lower alkyl, lower alkoxy, hydroxy, carboxy, -COO-lower alkyl, nitrilo, 5-tetrazol, (2-carboxylic acid pyrrolidin-1-yl)-2-oxo-ethoxy, N- hydroxycarbamimidoyl, 5-oxo[1,2,4]oxadiazolyl, 2-oxo-[1,2,3,5]oxathiadiazolyl, 5-thioxo[1,2,4]oxadiazolyl and 5-tert-butylsulfanyl-[1,2,4]oxadiazolyl; X' is -(CH2)n-; -(CH2)nCH(R&amp;lt;2&amp;gt;)-; -(CH2)nOCH2-; -NHCH2-; benzyl; -CH=C(R&amp;lt;2&amp;gt;)-; -CH(OH)CH2; or thiazol-2,5-diyl; R&amp;lt;2&amp;gt; is lower alkyl, lower alkoxy or benzyl and n is 0-3, or a pharmaceutically acceptable salt or mono- or diester thereof.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>EDAE1EEB-7957-4CFD-ABC7-B3A91418C427</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54610f7bd25799.93572857</gtr:outcomeId><gtr:patentId>JP4472333</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Therapeutic agent for depletion of an unwanted protein population from plasma</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the CRP molecules; or (ii) at least one of the ligands is capable of being bound by a ligand binding site present on a CRP molecule, and at least one other of the ligands is capable of being bound by a ligand binding site present on a serum amyloid P component (SAP) molecule.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>9BB7C50B-1651-4A56-A743-467DE30656D6</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>5464dbdb568194.68428038</gtr:outcomeId><gtr:patentId>AU200323400</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment and prevention of tissue damage</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of an agent capable of inhibiting serum amyloid P component (SAP) ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>D55E4DAC-95FF-4252-8A95-1C21CA22FE61</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>WPtjsMCTG9D</gtr:outcomeId><gtr:patentId>US7659299</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Compounds inhibiting the binding of SAP for treating osteoarthritis</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>01D15FF7-8370-4E72-9B03-E287323ABE24</gtr:id><gtr:impact>Potential therapy in development in collaboration with GlaxoSmithKline.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56d03bfd92c5c8.42084614</gtr:outcomeId><gtr:patentId>US9192668</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Combinations of SAP depleting agents and anti-SAP antibodies</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of an agent capable of inhibiting serum amyloid P component (SAP) ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>412B8771-4801-4304-A937-7AA59D7F9029</gtr:id><gtr:impact>Therapy in development.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>CP7HjFrQQXa</gtr:outcomeId><gtr:patentId>EP1633345</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Compounds inhibiting the binding of SAP for treating osteoarthritis</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of a non-proteinaceous agent for the preparation of a composition for the treatment of a subject having a disorder caused by a pathogenic protein, by therapeutic depletion of the pathogenic protein from the plasma of the subject; wherein the treatment comprises administering to the subject a dosage of the agent sufficient for therapeutic depletion; wherein the agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of the proteins in the presence thereof; and wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>20C4E6D7-B347-4A9D-B5F8-A6164F60D32B</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>XJF5PkPTkMY</gtr:outcomeId><gtr:patentId>US7045499</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Therapeutic agent</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of a compound which depletes serum amyloid P component from the circulation, in combination with an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>1157FA3A-B4F1-41F2-9450-AE7DC805C79C</gtr:id><gtr:impact>Potential therapy in development in collaboration with GlaxoSmithKline.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56d041fd2581d0.55363943</gtr:outcomeId><gtr:patentId>JP5695903</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Combinations of SAP depleting agents and anti-SAP antibodies</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>87B52A86-141C-406B-B57A-B6345C1281F4</gtr:id><gtr:impact>Combination is in full development with GSK with clinical trial in progress 2013.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>VdJnFkXDzS4</gtr:outcomeId><gtr:patentId>US7910106</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Combinations of SAP depleting agents and anti-SAP antibodies</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of a compound which depletes serum amyloid P component from the circulation, in combination with an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>43EE7B26-F35F-4CBB-A36D-EC3F8353CC0F</gtr:id><gtr:impact>Potential therapy in development in collaboration with GlaxoSmithKline.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>546120654d9686.83848549</gtr:outcomeId><gtr:patentId>AU2008267148</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Combinations of SAP depleting agents and anti-SAP antibodies</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>9CF6068B-324C-4977-B6DF-C80E1C40AF8C</gtr:id><gtr:impact>Potential therapy in development in collaboration with GlaxoSmithKline.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56d03f601cf1b3.12686319</gtr:outcomeId><gtr:patentId>AU2008358292</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Use</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Therapeutical and diagnostic agents for amyloidosis comprise molecules that inhibit the binding of serum amyloid P component to amyloid fibrils or analogues or homologues of the amyloid binding site on serum amyloid P component. The resolution of the complete three dimensional structure of serum amyloid P component enables inhibitors, binding site analogues and homologues to be designed by computer-aided molecular modelling.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>026D429C-501A-4959-8093-11A1DD61CEBD</gtr:id><gtr:impact>Potential therapy in development.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>YfC5UJSt41n</gtr:outcomeId><gtr:patentId>EP0714405</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Therapeutic and diagnostic agents for amyloidosis</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of a non-proteinaceous agent for the preparation of a composition for the treatment of a subject having a disorder caused by a pathogenic protein, by therapeutic depletion of the pathogenic protein from the plasma of the subject; wherein the treatment comprises administering to the subject a dosage of the agent sufficient for therapeutic depletion; wherein the agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of the proteins in the presence thereof; and wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>0696D3BC-4934-4FD7-B89B-0B8DC07CAABE</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>ViwzqwsvNPe</gtr:outcomeId><gtr:patentId>EP1418905</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Therapeutic agent for depletion of an unwanted protein population from plasma</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of an agent capable of inhibiting serum amyloid P component (SAP) ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>3CFDE636-B9D1-4860-85EC-609E8AC5E4A8</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>MdcFUVwkPcc</gtr:outcomeId><gtr:patentId>AU2004244815</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Compounds inhibiting the binding of SAP for treating osteoarthritis</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of a compound which depletes serum amyloid P component from the circulation, in combination with an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>06652EEF-F763-42D2-8D47-638F4C95714A</gtr:id><gtr:impact>Potential therapy in development in collaboration with GlaxoSmithKline.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58b6999c913c85.67467442</gtr:outcomeId><gtr:patentId>EP2173341</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Combinations of SAP depleting agents and anti-SAP antibodies</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Screening assays to identify therapeutic agents for amyloidosis.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>D67E0F26-BDBF-4445-B2F5-D3C609B4EFD1</gtr:id><gtr:impact>Enabling the development of potential therapies.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>M6gNTbnCBTP</gtr:outcomeId><gtr:patentId>US6126918</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Screening assays to identify therapeutic agents for amyloidosis</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of an agent capable of inhibiting serum amyloid P component (SAP) ligand binding activity or depleting SAP from the plasma of a subject for the production of a medicament for treatment or prevention of osteoarthritis in the subject.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>028BD4DE-9516-4DE0-A47C-6B99F7EAB8A0</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>JRrpLJ6sWqd</gtr:outcomeId><gtr:patentId>GB2420498</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Compounds inhibiting the binding of SAP for treating osteoarthritis</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>50617675-AC25-4C8C-AAC6-C803149F4DD4</gtr:id><gtr:impact>Licensing and collaboration agreement with GSK for full scale clinical development of this novel treatment is now in active progress, including humanisation of monoclonal antibodies. Phase 1 study conducted in 2012.. Further clinical trial in patients in progress 2013.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>e534ugdB1iM</gtr:outcomeId><gtr:patentId>WO2009000926</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Combinations of SAP-depleting agents and anti-SAP antibodies</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of a compound which depletes serum amyloid P component from the circulation, in combination with an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>87305387-6D08-4713-AED2-F0CC587FDD11</gtr:id><gtr:impact>Potential therapy in development in collaboration with GlaxoSmithKline.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58b698390013c4.40484743</gtr:outcomeId><gtr:patentId>KR101605448</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Combinations of SAP depleting agents and anti-SAP antibodies</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the CRP molecules; or (ii) at least one of the ligands is capable of being bound by a ligand binding site present on a CRP molecule, and at least one other of the ligands is capable of being bound by a ligand binding site present on a serum amyloid P component (SAP) molecule.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>DEB41AAE-0AF4-4561-A7B6-8094A9FFA795</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54610c40a12d18.35428700</gtr:outcomeId><gtr:patentId>EP1503800</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment and prevention of tissue damage associated with increased C-reactive protein production</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the CRP molecules; or (ii) at least one of the ligands is capable of being bound by a ligand binding site present on a CRP molecule, and at least one other of the ligands is capable of being bound by a ligand binding site present on a serum amyloid P component (SAP) molecule.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>3D4235D1-9746-43D3-847D-39D0DA615DCA</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>54610b2ac7d7f2.88514991</gtr:outcomeId><gtr:patentId>US7615543</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment and prevention of tissue damage</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of a non-proteinaceous agent for the preparation of a composition for the treatment of a subject having a disorder caused by a pathogenic protein, by therapeutic depletion of the pathogenic protein from the plasma of the subject; wherein the treatment comprises administering to the subject a dosage of the agent sufficient for therapeutic depletion; wherein the agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of the proteins in the presence thereof; and wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>0B8B841C-31E6-47D6-BC33-0A45C5A625E6</gtr:id><gtr:impact>Therapy in development.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>fpVSr4Nz2sG</gtr:outcomeId><gtr:patentId>EP1820501</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Therapeutic agent for depletion of an unwanted protein population from plasma</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>5E3FFB11-14EC-46AC-8030-CAB6157119AA</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>546105cd35b556.18390299</gtr:outcomeId><gtr:patentId>US7390795</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment and prevention of tissue damage</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method for the treatment or prevention of tissue damage in a subject having an inflammatory and/or tissue damaging condition, which comprises administering to the subject an effective amount of a compound capable of inhibiting the binding of C-reactive protein (CRP) to an autologous or extrinsic ligand.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>90A00F5D-D289-4F22-A091-26E945782825</gtr:id><gtr:impact>Potential therapy.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>546117aa19c713.26804558</gtr:outcomeId><gtr:patentId>US8039222</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment and prevention of tissue damage</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of a compound which depletes serum amyloid P component from the circulation, in combination with an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>18D3AD4D-5582-4DEA-9A1F-FA1DB4B61320</gtr:id><gtr:impact>Potential therapy in development in collaboration with GlaxoSmithKline.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56d0434a4b0dc3.93976588</gtr:outcomeId><gtr:patentId>ZL200880103452.5</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Combinations of SAP depleting agents and anti-SAP antibodies</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Use of a non-proteinaceous agent for the preparation of a composition for the treatment of a subject having a disorder caused by a pathogenic protein, by therapeutic depletion of the pathogenic protein from the plasma of the subject; wherein the treatment comprises administering to the subject a dosage of the agent sufficient for therapeutic depletion; wherein the agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of the proteins in the presence thereof; and wherein at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the proteins.</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>3519EE98-4179-4B75-929F-E2098951978C</gtr:id><gtr:impact>Potential therapy in development.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>tDqFD6dEA48</gtr:outcomeId><gtr:patentId>US8173694</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Therapeutic agent</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component</gtr:description><gtr:grantRef>G7900510</gtr:grantRef><gtr:id>DA46B704-C086-4212-81A3-90D7CC5052D1</gtr:id><gtr:impact>Potential therapy in development in collaboration with GlaxoSmithKline. First in human patient studies in progress 2013.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>cFQ79AEYc9V</gtr:outcomeId><gtr:patentId>WO2009000926</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Use</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Amyloidosis Diagnostics</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>Guidelines on the diagnosis and management of AL amyloidosis. Guidelines Working Group of UK Myeloma Forum; British Committee for Standards in Haematology, British Society for Haematology.</gtr:guidelineTitle><gtr:id>FBFE3DCF-9322-4CF6-955E-4E991A1D2256</gtr:id><gtr:impact>The National Amyloidosis Centre sees more than 3,000 patients per year. The diagnostic service provided by the Centre is based on radiolabelled scintigraphy, a safe, non-invasive diagnostic and monitoring technique invented by Mark Pepys and developed into a routine clinical test by Philip Hawkins during his PhD (1986-89). Due to its complexity, sophistication and cost, the method is available only in the National Amyloidosis Centre and in one other Centre, in Groningen, Holland, which is collaboratively supported by the National Amyloidosis Centre. However the test is the envy of the world and has enabled the National Amyloidosis Centre to develop world leading experience and expertise in all aspects of amyloidosis, involving the largest and most diverse cohort of patients with this disease in the world.
The Centre has delivered both new fundamental scientific knowledge and substantial improvements in clinical management leading to greatly improved patient survival, the best for this disease in the world.</gtr:impact><gtr:outcomeId>R87w6S3CP89</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Successful immunisation induces a protective immune response against particular component(s) of the target pathogen, the so-called immunogen(s). For some diseases the immunogens are not known and for others they are difficult and expensive to produce, transport and administer, for example influenza vaccine must be produced in millions of chicken eggs. A very attractive potential solution is to inject the DNA gene encoding the immunogen rather than the immunogen itself. In this process, known as DNA vaccination, the DNA enters cells, predominantly at the site of injection, and causes them to produce the immunogen locally within the body. DNA vaccination works well and stimulates excellent protective immunity against a variety of different infections, and even some cancers, in mice, horses, dogs, rabbits and pigs. But in humans and other primates, and in cows and sheep, the immune response to DNA vaccination is very feeble. Despite enormous academic and pharmaceutical industry efforts, the reasons for this failure have not been understood or overcome. We previously discovered, in work funded by the MRC, that a protein in human plasma, known as serum amyloid P component (SAP), is the only normal plasma protein which binds avidly to DNA. We have now found that, in each of the animal species in which DNA vaccination is effective, this protein is either absent or, if it is present, it binds only weakly to DNA. In contrast, non-human primates, cows and sheep share with humans the presence of SAP proteins which strongly bind to DNA. We believe that binding of DNA by SAP may be responsible for blocking induction of immune responses by DNA and that removal of SAP may overcome this inhibition. SAP contributes to important human diseases, amyloidosis and Alzheimer's disease, and, in MRC funded work towards treatment for these conditions, we have previously developed a drug, CPHPC, which safely removes almost all SAP from the blood in humans. Another laboratory has recently reported that the presence of human SAP inhibits DNA vaccination in mice and that this effect is reversed by our drug, CPHPC. These observations confirm our hypothesis. We are now undertaking the first human clinical study of DNA vaccination after SAP depletion, funded by an MRC DCS award. We will measure the immune responses to HIV-1 in normal adult men, comparing a group in whom SAP has been completely depleted at the time of DNA vaccination and a control group vaccinated without SAP depletion. We predict that SAP depletion at the time of vaccination will enhance the immune response. The DNA vaccine to be tested is a promising new vaccine against HIV-AIDS, developed and manufactured with previous MRC awards. A positive result, consistent with improved protective immunity against HIV-1, will be very encouraging. Furthermore, proof of the concept that SAP depletion can enhance immune responses to DNA vaccination in humans will open up this approach for the many other diseases for which effective vaccination does not yet exist and in which it could have therapeutic as well as prophylactic benefits. Success in the clinical trial undertaken here with an HIV-1 vaccine will establish a critical proof of concept, opening the way to general application of our new approach. The clinical trial has begun. The first two subjects have been successfully screened and randomised and have been admitted to the CRF. CPHPC infusion has taken place and they have now received the first DNA vaccination. The programme is funded by MRC DCS award MR/J008605/1.</gtr:description><gtr:id>FAF9E9C2-47E4-4C27-9603-9932AAB23ECD</gtr:id><gtr:impact>The intervention is still in early stage clinical assessment.</gtr:impact><gtr:outcomeId>UdSPYHzumst</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Depletion of serum amyloid P component to enhance the immune response to DNA vaccination</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14680</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Prof Sir Mark Pepys identified C-reactive protein (CRP) as a therapeutic target in clinical situations in which there is pre-existing tissue damage and high level production of CRP. Novel CRP inhibitor compounds are currently in pre-clinical development. After extensive evaluation the original compound, BPC8, for the development of which the DCS award was given in 2010, was found not be optimal for further development. In 2012 the MRC awarded Sir Mark additional funds for a back up chemistry programme to rationally design and synthesise new candidate molecules drawing on the results so far with BPC8. This programme continues and two promising candidate molecules are currently being synthesised by a CRO. In a progress report to the MRC Sir Mark described the novel molecules which have been designed, synthesised and tested so far. Unsurprisingly for such a novel programme none evaluated so far have been optimal for development, however the results of these evaluations have provided important knowledge for the design of subsequent compounds. Two promising compounds are currently being synthesised by a CRO and are due for delivery early November. Unfortunately the MRC have deemed the programme to now be too different from the original plan and have decided to terminate the award. A termination plan has been submitted and we await approval. In the meantime evaluation of the newest compounds will continue with a view to seeking further funds if one or more of these should prove worthy of full scale pre-clinical evaluation.</gtr:description><gtr:id>7A7D921F-13DC-4D6F-9C7D-9BE16D2C61A8</gtr:id><gtr:impact>The work was published in Nature in 2006 and was the subject of the cover illustration and additional material in the journal. It was recognised by commentaries in the New England Journal of Medicine and Nature Structural Biology as a seminally important piece of work.</gtr:impact><gtr:outcomeId>8A0359E2F2E</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Inhibitors of C-reactive protein</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Transthyretin is an inherently amyloidogenic protein and forms microscopic amyloid deposits in all individuals over the age of 80 years. In some aged individuals massive transthyretin amyloid deposition in the heart causes fatal senile cardiac amyloidosis, a condition which is rarely diagnosed but is almost certainly much more prevalent than currently recognised. Most of the &amp;gt;100 rare mutations in the human transthyretin gene increase the amyloidogenicity of the respective variant proteins and cause autosomal dominant adult onset hereditary transthyretin amyloidosis, usually presenting as familial amyloid polyneuropathy. There is currently no effective treatment for this uniformly fatal disease. Since transthyretin amyloidogenesis involves misfolding and dissociation of the native tetrameric structure of the protein, a rational therapeutic approach is the use of small molecule ligands which are specifically bound by transthyretin and stabilise its native structure and assembly. Prof Sir Mark Pepys and his research group are developing novel transthyretin superstabiliser compounds in collaboration with GlaxoSmithKline. The compounds are currently at medicinal chemistry/ early non-clinical testing and refinement stage. As GSK licensed this programme in 2010 they are now the principle source of funding.</gtr:description><gtr:id>ACD40944-040D-4A1D-B853-D9ED32AD9767</gtr:id><gtr:impact>The development programme is still at an early stage. Novel transthyretin stabilising compounds have been identified. These are being evaluated and refined for eventual clinical testing. New Intellectual Property has arisen and is being protected appropriately.</gtr:impact><gtr:outcomeId>eh2wpUwrkZa</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Transthyretin superstabilisers</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>My research supported by the MRC Programme Grant since 1979 first identified serum amyloid P component as a potential therapeutic target in amyloidosis and Alzheimer's disease. I designed a high throughput screen for inhibitors of ligand binding by serum amyloid P component and, in collaboration with Roche, 100,000 compounds in their library were screened. The best lead was developed into a drug which was eventually licensed exclusively to myself and UCL for clinical testing in humans. I discovered that it had a completely novel pharmacological mechanism of action which caused rapid and almost total depletion of circulating serum amyloid P component. This was reported in Nature in 2002 and received major coverage in the scientific and lay media, including mainstream BBC, ITV, US and European television and radio. It was identified by the American Chemical Society as one of the medicinal chemistry highlights of 2002. My invention of the mechanism responsible is covered by granted patents.</gtr:description><gtr:id>AFE7FA5B-145A-4A0E-9309-050FCB878358</gtr:id><gtr:impact>Our first into man open label phase 2 study in systemic amyloidosis showed promising signs of clinical efficacy. Our open label first clinical study in Alzheimer's disease showed complete safety and dramatic biochemical efficacy in depleting SAP from the CSF. We have now out licensed CPHPC to GSK as part of the package for treatment of systemic amyloidosis by my newly invented approach detailed separately. Other workers have used my approach to design drugs targeting cholera and shiga toxins, while I have used it to design successfully the first inhibitor of human C-reactive protein, as reported in another entry in this form. The same strategy also led to our novel drugs targeting transthyretin for treatment and prevention of transthyretin amyloidosis.</gtr:impact><gtr:outcomeId>A6F883044CC</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>CPHPC</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://clinicaltrials.gov/show/NCT01406314</gtr:url><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The tissue damage in systemic amyloidosis which is responsible for disease and death is caused by accumulation of amyloid deposits in the tissues and organs. There are currently no clinical treatments which directly target amyloid deposits for elimination. The Pepys team first identified and validated human serum amyloid P component (SAP) as a therapeutic target in amyloidosis in the mid 1990s. In vitro, SAP both enhances amyloid fibril formation and protects amyloid fibrils from proteolytic degradation by macrophages. In collaboration with Roche they developed the novel palindromic bis-D-proline compound (R)-1-[6-[(R)-2-Carboxy-Pyrrolidin-1-yl]-6-oxo-Hexanoyl]Pyrrolidine-2-Carboxylic acid (CPHPC), which was intended to prevent SAP from binding to amyloid fibrils in vivo and dissociate bound SAP from amyloid deposits (Nature 2002). CPHPC is avidly bound by human SAP in a complex composed of two native pentameric SAP molecules cross linked by 5 bivalent CPHPC molecules. The complex is perceived as abnormal by the liver and instantly cleared, leading to profound depletion of SAP from the circulation which persists for as long as the drug is administered (PNAS 2009). Targeted depletion of a pathogenic protein by a small molecule drug constitutes a potent, novel pharmacological mechanism. The depletion of plasma SAP also clears most of the SAP from amyloid deposits but the affinity of SAP for CPHPC is insufficient to produce complete dissociation of all SAP from amyloid deposits in the face of the continuous production of 50-100 mg of new SAP per day and the avid binding of SAP to amyloid fibrils. CPHPC is well tolerated by patients and has been administered to more than 60 subjects for a total of more than 50 patient years without any adverse effects. But up to about 10% of the amyloid associated SAP remains in major visceral amyloid deposits even after months of continuous CPHPC treatment. Nevertheless we have not observed any new amyloid accumulation in patients on CPHPC, even those in whom there was progressive deposition before and after CPHPC exposure. Furthermore there were encouraging signs of prolonged renal and possibly patient survival in subjects receiving CPHPC. However we have not detected any amyloid regression. Thus while CPHPC may be a useful adjunct to other therapy for amyloidosis it does not itself promote elimination of the deposits. Pentraxin acquired full ownership of CPHPC from Roche in December 2008.
The capacity of CPHPC to clear essentially all SAP from the circulation, while leaving significant amounts of SAP specifically bound in the amyloid deposits, suggested the possibility of using the residual SAP as an amyloid-specific target for antibodies which can invoke physiological clearance of amyloid from the tissues. Depletion of circulating SAP crucially allows such antibodies to be administered safely and effectively. This approach is unrelated to the function of SAP itself and simply uses SAP as a passive amyloid-specific target. It has been remarkably successful in experimental models (Nature 2010) and should be applicable to all forms of amyloidosis although its safety and efficacy, especially for amyloid in different organs and tissues, will have to be, and is being, carefully evaluated. GlaxoSmithKline licensed the invention of this first in class combination of a small molecule drug and a monoclonal antibody from Pentraxin in February 2009. They have already fully humanised one of our optimal mouse monoclonal anti-human SAP antibodies and clinical testing is currently underway. In 2012 they conducted a Phase 1, Open Label, Dose Characteristic Study to Investigate the pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous and subcutaneous doses of CPHPC in patients with systemic amyloidosis (http://www.clinicaltrials.gov/ct2/show/NCT01406314?term=amyloid+gsk&amp;amp;rank=4), enabling progression to a single dose first in human study of anti-SAP antibodies co-administered with CPHPC in patients with systemic amyloidosis, which is currently underway http://www.clinicaltrials.gov/ct2/show/NCT01777243?term=amyloid+gsk&amp;amp;rank=2. Meanwhile our original patent applications, licensed to GSK for this programme, are progressing and GSK are filing new patents as the work proceeds.</gtr:description><gtr:id>4F974FCE-35BF-48ED-B4D5-BFFD0E7C4BF3</gtr:id><gtr:impact>Combination currently in clinical trials with very encouraging results and a first publication being prepared for submission. The intervention has already been granted Orphan Drug status by the EMA and been adopted as their flagship candidate for adaptive licensing.</gtr:impact><gtr:outcomeId>HrpBacsC256</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Combination of CPHPC and anti SAP mAb</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://www.clinicaltrials.gov/show/NCT01777243</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The 30 years of MRC support for this programme, 1979-2009, led to development of the CPHPC drug. This was ready for clinical trials in 2000 but the prolonged battle for funding support from the MRC and pharma was unsuccessful until 2009 when some of the IP was licensed to GSK for treatment of systemic amyloidosis. Five years later the clinical trial of that treatment has been shown to be successful, winning major milestone awards, Orphan Drug status, etc. The MRC completely failed to either understand the need for studies in Alzheimer's disease and dementia, or to provide funding for these. However the NIHR first provided core support for the Pepys team in 2012, followed by &amp;pound;1 million for trial preparations in 2013, and finally a Strategic Award in 2014 of &amp;pound;2.571 million to fund the clinical trial. Pepys has now also been invited by the Alzheimer's Society-Alzheimer's Drug Discovery Foundation to apply for two new grants of $1.5 million each for trials of his drug in cerebral amyloid angiopathy and traumatic brain injury respectively.</gtr:description><gtr:id>25B04388-3EE9-4B65-9D3E-728EA77BDF3B</gtr:id><gtr:impact>In addition to the generous funding from the NIHR, contrasting sharply with the failure of the MRC to support one of the major outputs from its previous continuous funding of Pepys's research since 1969, the work on CPHPC for Alzheimer's and related diseases is also strongly supported by GSK. They are critically important partners in development at all levels in a synergistic relationship which is a paradigm of collaboration between academia and the pharma industry.</gtr:impact><gtr:outcomeId>5460b4b73cbf29.74502695</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Clinical trials of CPHPC for Alzheimer's and other neurodegenerative diseases</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>monoclonal antibodies to SAP - designed to bind to SAP and clear amyloid</gtr:description><gtr:id>F4B79939-D832-4A68-B3D1-8A8EEFAC3D90</gtr:id><gtr:impact>In 2009 GSK licensed Pepys's patents on his invention of the obligate therapeutic partnership of CPHPC and monoclonal anti-SAP antibodies for treatment of systemic amyloidosis. The invention was published in Nature 4 November 2010. It has now been developed for human use and is in its first in human clinical trial with very encouraging results. Orphan drug status has been conferred by the EMA and it is their flagship candidate for adaptive licensing.</gtr:impact><gtr:outcomeId>iFWssdE8hqv</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Anti-SAP mAbs</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The human pentraxin proteins, serum amyloid P component (SAP) and C reactive protein (CRP) are important in routine clinical diagnosis, SAP for systemic amyloidosis and CRP for monitoring the non-specific acute phase response. They are also targets for novel therapies currently in development but their roles in health and disease are controversial. Thus, both for clinical use and to rigorously elucidate their functions, structurally and functionally intact, pharmaceutical grade preparations of the natural, authentic proteins are required. Prof Sir Mark Pepys's group has produced and characterised the first such preparations from normal human donor plasma.</gtr:description><gtr:id>C1133E3C-EBC7-445E-ABDD-8DDAEFE04395</gtr:id><gtr:impact>These structurally and functionally intact, pharmaceutical grade preparations of the natural, authentic proteins will enable rigourous elucidation of their functions as well as being suitable for clinical use.</gtr:impact><gtr:outcomeId>KrQFY6dLJcw</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GMP SAP and CRP</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A range of novel antibodies to human serum amyloid P component have been developed and characterised for use in in vitro and in vivo experimental, therapeutic and diagnostic studies.</gtr:description><gtr:id>64D7F84D-6E30-444E-BA72-FC0C53A8231A</gtr:id><gtr:impact>Publication of a novel assay method and unique clinical research results.</gtr:impact><gtr:outcomeId>V3mQarWNZgK</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Anti-serum amyloid P component antibodies</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>IRMA assay to measure SAP levels in serum, plasma and CSF at the ng level</gtr:description><gtr:id>CE33F080-1E6D-45DD-8D79-180D5F1766D1</gtr:id><gtr:impact>Ability to sensitively measure the amount of SAP present in samples of serum, plasma and CSF.</gtr:impact><gtr:outcomeId>Wy5fWETDCDv</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Assays for human SAP</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Transgenic mouse capable of overexpressing SAA on ingestion of tetracycline, and forming amyloid</gtr:description><gtr:id>111FA803-957C-464B-910A-C657C86C78A6</gtr:id><gtr:impact>New mouse model that develops amyloidosis without having to induce inflammation. This is kinder to the mice and also more closely resembles the human disease</gtr:impact><gtr:outcomeId>DA9eWmsM6gS</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>SAA transgenic mouse model of amyloidosis</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Pentraxin Therapeutics Limited</gtr:companyName><gtr:description>The Company was set up by UCL Business (the commercial arm of UCL) to hold and commercialise all intellectual property arising from Professor Sir Mark's work at UCL. Pentraxin has been financed by UCL Business and the current shareholdings are held as 45% by Professor Sir Mark Pepys, 45% by UCL Business, 5% each by Professor Philip Hawkins and Professor Steve Wood. There are four Directors, Professor Sir Mark Pepys and Mr Cengiz Tarhan (representing UCL Business), Professor Hawkins and Professor Wood. The majority of Pentraxin's research work is carried out at UCL with certain aspects being out-sourced to third parties. The company has three main programmes under development: 1) CPHPC, a small molecule compound, in combination with an anti- Serum amyloid P component (SAP) mAb for the treatment of systemic amyloidosis. This programme was licensed by GSK in 2009 2) Inhibitors of C-reactive protein (CRP), developed for the treatment and prevention of tissue damage; and 3) a compound for the treatment of hereditary systemic and senile cardiac amyloidosis targeting depletion of transthyretin. This programme was licensed by GSK in 2010. Sir Mark is also preparing to trial his drug CPHPC in three different studies in patients with Alzheimer's disease, cerebral amyloid angiopathy and traumatic brain injury respectively . The company's website can be found at www.pentraxin.com</gtr:description><gtr:id>F2122A15-BA2B-4D54-9F8B-C29F841C2664</gtr:id><gtr:impact>The company has supported Professor Sir Mark's research work for many years and facilitated the licensing of CPHPC from Roche and proceeded with the GMP manufacture of CPHPC - for use in clinical trials on patients with systemic amyloidosis at UCL. A licence deal was signed with GSK in February 2009 to enable GSK to develop an application combining a humanised antibody with CPHPC to eliminate amyloid deposits. Clinical trials with the combination are currently in progress (see URLs http://www.clinicaltrials.gov/ct2/show/NCT01406314?term=amyloid+gsk&amp;amp;rank=4 and http://www.clinicaltrials.gov/ct2/show/NCT01777243?term=amyloid+gsk&amp;amp;rank=2.). In November 2010 GSK also licensed Prof Sir Mark Pepys's transthyretin superstabiliser programme. Sir Mark's group worked closely with GSK on this programme. Sir Mark's group also collaborated closely with GSK's scientific advisory arm, Scinovo, on his CRP inhibitor molecule programme.</gtr:impact><gtr:outcomeId>5DC5C6497CC</gtr:outcomeId><gtr:url>http://pentraxin.wordpress.com/</gtr:url><gtr:yearCompanyFormed>2004</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>6D3421A8-6AD9-4D75-99B4-13A8A3F786F1</gtr:id><gtr:title>Evaluation and management of the cardiac amyloidosis.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3dffd764237e86744711a8de44375a74"><gtr:id>3dffd764237e86744711a8de44375a74</gtr:id><gtr:otherNames>Selvanayagam JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>CFDFE80658A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12A9241F-DB1C-458C-A914-0A3C4CF0C1AE</gtr:id><gtr:title>Renal biopsy is a relatively safe procedure in cases of suspected amyloidosis and a valuable tool in excluding non-AL forms of the disease.</gtr:title><gtr:parentPublicationTitle>Internal medicine journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4097327de79c7f9118988ab900bbe699"><gtr:id>4097327de79c7f9118988ab900bbe699</gtr:id><gtr:otherNames>Gibbs SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1444-0903</gtr:issn><gtr:outcomeId>XYWYknxG4K5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CE6CB77-8F0F-4286-BDAC-85EE939AB903</gtr:id><gtr:title>Cardiac transplantation should be considered in selected patients with either AL or hereditary forms of amyloidosis: the UK National Amyloidosis Centre experience.</gtr:title><gtr:parentPublicationTitle>Internal medicine journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4097327de79c7f9118988ab900bbe699"><gtr:id>4097327de79c7f9118988ab900bbe699</gtr:id><gtr:otherNames>Gibbs SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1444-0903</gtr:issn><gtr:outcomeId>6D056E6F0B7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EA6833C-8E8D-4073-8B0E-328B66AB6CE9</gtr:id><gtr:title>Bifunctional crosslinking ligands for transthyretin.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56a12cb17317ac844dd3c546061d293c"><gtr:id>56a12cb17317ac844dd3c546061d293c</gtr:id><gtr:otherNames>Mangione PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56d02c5d8e2686.71879624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B504358-76E3-4553-B801-3D19D1D12290</gtr:id><gtr:title>Attention to detail in the selection of words in epidemiologic research reports.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a83695b7c5b808a74aaf984a221dd067"><gtr:id>a83695b7c5b808a74aaf984a221dd067</gtr:id><gtr:otherNames>Greenland P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>545a3f8434db95.75014550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>908AA9A5-27A4-49F1-A0BD-A98791039789</gtr:id><gtr:title>An unusual phenotype in Muckle-Wells syndrome associated with NLRP3 E311K.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4938562a94d1b20a3e4e34de9b13fd4f"><gtr:id>4938562a94d1b20a3e4e34de9b13fd4f</gtr:id><gtr:otherNames>Murphy G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>itnXvK6FWE7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DC8A93D-A428-45FB-8A4A-842D844C8A0E</gtr:id><gtr:title>C-reactive protein is neither a marker nor a mediator of atherosclerosis.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f38404ed7f6d03e85ca14c4790282d"><gtr:id>66f38404ed7f6d03e85ca14c4790282d</gtr:id><gtr:otherNames>Pepys MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1745-8323</gtr:issn><gtr:outcomeId>3DD72E16228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>795B5EC6-1513-4075-8D4A-AC49CAA6ACC8</gtr:id><gtr:title>Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations.</gtr:title><gtr:parentPublicationTitle>Archives of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd3a0dd22bb73ec771853136f4f70660"><gtr:id>cd3a0dd22bb73ec771853136f4f70660</gtr:id><gtr:otherNames>Leslie KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0003-987X</gtr:issn><gtr:outcomeId>A87759292AB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15C8794B-2226-45D0-9629-2DDDDA138878</gtr:id><gtr:title>Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis.</gtr:title><gtr:parentPublicationTitle>Bone marrow transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38258827f27f06a7bfdf9259c49bc19f"><gtr:id>38258827f27f06a7bfdf9259c49bc19f</gtr:id><gtr:otherNames>Perz JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0268-3369</gtr:issn><gtr:outcomeId>91A520C01EB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7916C27-161F-48DD-8DA8-640AF017B502</gtr:id><gtr:title>Complement factor H binds to denatured rather than to native pentameric C-reactive protein.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29c93f2d9d4c754ff4c4362079eb33d8"><gtr:id>29c93f2d9d4c754ff4c4362079eb33d8</gtr:id><gtr:otherNames>Hakobyan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>288EB15DCD5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>419E469A-2453-4E85-A6F5-F0345C0EA426</gtr:id><gtr:title>Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up.</gtr:title><gtr:parentPublicationTitle>Journal of cutaneous medicine and surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e228d79094f73b09b2ef34ff02107af2"><gtr:id>e228d79094f73b09b2ef34ff02107af2</gtr:id><gtr:otherNames>Ross JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1203-4754</gtr:issn><gtr:outcomeId>FJ85tbJDFQ1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1119A300-7A30-4513-B2D5-064C00A34AAA</gtr:id><gtr:title>AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbf0725706c062574f880feafb8d0c4e"><gtr:id>dbf0725706c062574f880feafb8d0c4e</gtr:id><gtr:otherNames>Wechalekar AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>9CE8A87EA55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7A34939-136A-4F66-B877-3B18FC58BAA3</gtr:id><gtr:title>Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc39bd1ec01b3f71dbde14b5bec16710"><gtr:id>bc39bd1ec01b3f71dbde14b5bec16710</gtr:id><gtr:otherNames>Kolstoe SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>F10C4B39588</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AC16FC8-1DB9-42A3-B4F2-6824A1B0FE68</gtr:id><gtr:title>Use of canakinumab in the cryopyrin-associated periodic syndrome.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce7d0fb8f12f683a2fc8e3e9fa56248"><gtr:id>1ce7d0fb8f12f683a2fc8e3e9fa56248</gtr:id><gtr:otherNames>Lachmann HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>13D113F0F7A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61268086-72EC-4C5A-A38F-B63873E7A0FA</gtr:id><gtr:title>Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component.</gtr:title><gtr:parentPublicationTitle>Journal of molecular recognition : JMR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a909825eb4f83c3696b421118c534ef5"><gtr:id>a909825eb4f83c3696b421118c534ef5</gtr:id><gtr:otherNames>Mikolajek H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0952-3499</gtr:issn><gtr:outcomeId>pm_13505_25_21360619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C200334F-C6D4-4CA2-A657-2E719BB4BB45</gtr:id><gtr:title>Organ transplantation in hereditary apolipoprotein AI amyloidosis.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb8299846a6d50c267ef12b2521ad7f"><gtr:id>2cb8299846a6d50c267ef12b2521ad7f</gtr:id><gtr:otherNames>Gillmore JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>E4F10218D8F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C20DA703-7F8C-49E9-81C5-C19B60EAAC27</gtr:id><gtr:title>Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis.</gtr:title><gtr:parentPublicationTitle>Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f9f0a54fe1766f2c2f1fa4cffbfbd11"><gtr:id>1f9f0a54fe1766f2c2f1fa4cffbfbd11</gtr:id><gtr:otherNames>Hazenberg BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1350-6129</gtr:issn><gtr:outcomeId>48EBCFF187B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E09F83A-4025-4669-8355-9AF156879935</gtr:id><gtr:title>Systemic amyloidosis and the gastrointestinal tract.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef4512f8fd1df086398fd3391a2a91f0"><gtr:id>ef4512f8fd1df086398fd3391a2a91f0</gtr:id><gtr:otherNames>Sattianayagam PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-5045</gtr:issn><gtr:outcomeId>42B279E0219</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E2CB201-5949-4B5F-A50D-310792635B0F</gtr:id><gtr:title>AA amyloidosis complicating hyperimmunoglobulinemia D with periodic fever syndrome: a report of two cases.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce7d0fb8f12f683a2fc8e3e9fa56248"><gtr:id>1ce7d0fb8f12f683a2fc8e3e9fa56248</gtr:id><gtr:otherNames>Lachmann HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>7DC583F95EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59598B63-DBE8-4239-BE91-11C8CE5715AE</gtr:id><gtr:title>Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis.</gtr:title><gtr:parentPublicationTitle>The American journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f9f0a54fe1766f2c2f1fa4cffbfbd11"><gtr:id>1f9f0a54fe1766f2c2f1fa4cffbfbd11</gtr:id><gtr:otherNames>Hazenberg BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0002-9343</gtr:issn><gtr:outcomeId>182FD42B615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE161721-DFDE-4626-B0A7-0E21FF43755B</gtr:id><gtr:title>Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbf0725706c062574f880feafb8d0c4e"><gtr:id>dbf0725706c062574f880feafb8d0c4e</gtr:id><gtr:otherNames>Wechalekar AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>3338A042F85</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E89BB9C-3B4D-477B-B43C-99E2BF4919E7</gtr:id><gtr:title>Hereditary auto-inflammatory disorders and biologics.</gtr:title><gtr:parentPublicationTitle>Springer seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6b402242cf475039f153da14328f27e1"><gtr:id>6b402242cf475039f153da14328f27e1</gtr:id><gtr:otherNames>Church LD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0344-4325</gtr:issn><gtr:outcomeId>3A2AF3390D4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A14F5DD0-42E7-4E29-8FD9-B5D2498BB4AF</gtr:id><gtr:title>C-reactive protein is essential for innate resistance to pneumococcal infection.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e722caed5ab755cbbee8a96491d55440"><gtr:id>e722caed5ab755cbbee8a96491d55440</gtr:id><gtr:otherNames>Simons JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>545a3f83d5a838.21537329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>129098D3-2AFE-44BC-A9AF-98EE22D2225F</gtr:id><gtr:title>Systemic amyloidosis: getting to the heart of the matter.</gtr:title><gtr:parentPublicationTitle>British journal of hospital medicine (London, England : 2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8aa567c4ecc73aa449f2db7d7b387f5"><gtr:id>a8aa567c4ecc73aa449f2db7d7b387f5</gtr:id><gtr:otherNames>Hawkins PN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1750-8460</gtr:issn><gtr:outcomeId>gEJp8igtrtY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BDCFF9D-9794-4FF4-A803-3D0A646AA99C</gtr:id><gtr:title>Hereditary systemic amyloidosis due to Asp76Asn variant ?2-microglobulin.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0f47e4a8312b89acfbcc528be608827"><gtr:id>b0f47e4a8312b89acfbcc528be608827</gtr:id><gtr:otherNames>Valleix S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_13505_25_22693999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D640931A-9496-475E-865B-BF2601105F35</gtr:id><gtr:title>Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6cddc56f77f8994a72ae410274f51dc"><gtr:id>b6cddc56f77f8994a72ae410274f51dc</gtr:id><gtr:otherNames>Richards DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56d02a9255ec84.79743326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D03CBF3-CB20-4A40-8FBC-E4BC07252C72</gtr:id><gtr:title>Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb8299846a6d50c267ef12b2521ad7f"><gtr:id>2cb8299846a6d50c267ef12b2521ad7f</gtr:id><gtr:otherNames>Gillmore JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>c14WH3Pij9B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5744BF8-2A93-452D-A62E-FD8128A2BF02</gtr:id><gtr:title>Laryngeal presentation of systemic apolipoprotein A-I-derived amyloidosis.</gtr:title><gtr:parentPublicationTitle>The Laryngoscope</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21aee5a57460c806e557a43a2d57f50f"><gtr:id>21aee5a57460c806e557a43a2d57f50f</gtr:id><gtr:otherNames>Hazenberg AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0023-852X</gtr:issn><gtr:outcomeId>5D8E12F2369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D688FAA-395E-465C-BDB0-C9599E5ADCD7</gtr:id><gtr:title>Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis.</gtr:title><gtr:parentPublicationTitle>Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a9ba6e8e0d7f9a88cf065a0abc30a8d"><gtr:id>3a9ba6e8e0d7f9a88cf065a0abc30a8d</gtr:id><gtr:otherNames>Maceira AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1097-6647</gtr:issn><gtr:outcomeId>F64ABDE7924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>268641DB-751A-40CF-AF49-5422612D731B</gtr:id><gtr:title>Disease-associated prion protein is not detectable in human systemic amyloid deposits.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/458ba87b7b0d20eff58e31fac88e2544"><gtr:id>458ba87b7b0d20eff58e31fac88e2544</gtr:id><gtr:otherNames>Tennent GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>AEE8752E51F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBF7D77E-AC0A-4D7A-805A-6BD6D233724E</gtr:id><gtr:title>Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb8299846a6d50c267ef12b2521ad7f"><gtr:id>2cb8299846a6d50c267ef12b2521ad7f</gtr:id><gtr:otherNames>Gillmore JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>28F44FBBD5E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FC497D3-1249-45F6-AF06-5D5341541853</gtr:id><gtr:title>Amyloidosis and primary biliary cirrhosis, Rodriguez-Luna et al.</gtr:title><gtr:parentPublicationTitle>Digestive diseases and sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbeadc30794a5e9ee34583712a1b3d5b"><gtr:id>cbeadc30794a5e9ee34583712a1b3d5b</gtr:id><gtr:otherNames>Goodman HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0163-2116</gtr:issn><gtr:outcomeId>A3E6B41A8FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1BAB60DB-5BDE-4240-8A33-0ACA5D676CD7</gtr:id><gtr:title>Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb8299846a6d50c267ef12b2521ad7f"><gtr:id>2cb8299846a6d50c267ef12b2521ad7f</gtr:id><gtr:otherNames>Gillmore JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>FejFHj6hjEp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40ECE498-038D-4ECF-8725-FB2383694103</gtr:id><gtr:title>Systemic amyloidosis.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce7d0fb8f12f683a2fc8e3e9fa56248"><gtr:id>1ce7d0fb8f12f683a2fc8e3e9fa56248</gtr:id><gtr:otherNames>Lachmann HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>5F33FB1CADB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6DD8C79-56A6-442D-9714-10DF98B46F3B</gtr:id><gtr:title>In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce7d0fb8f12f683a2fc8e3e9fa56248"><gtr:id>1ce7d0fb8f12f683a2fc8e3e9fa56248</gtr:id><gtr:otherNames>Lachmann HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>45B0711823A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C2B4D41-9B37-4706-8802-0D73465C6829</gtr:id><gtr:title>C-reactive protein, fibrinogen, and cardiovascular disease prediction.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00954130f581451305ebfe461866731f"><gtr:id>00954130f581451305ebfe461866731f</gtr:id><gtr:otherNames>Emerging Risk Factors Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_13505_25_23034020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E64310CB-87B0-45B7-B978-9006265B3D24</gtr:id><gtr:title>Human plasma fibrinogen is synthesized in the liver.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/458ba87b7b0d20eff58e31fac88e2544"><gtr:id>458ba87b7b0d20eff58e31fac88e2544</gtr:id><gtr:otherNames>Tennent GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>FCA15E15EA7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D2E6BFC-22DA-466B-9699-8C9664B421DC</gtr:id><gtr:title>Developments in the scientific and clinical understanding of autoinflammatory disorders.</gtr:title><gtr:parentPublicationTitle>Arthritis research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce7d0fb8f12f683a2fc8e3e9fa56248"><gtr:id>1ce7d0fb8f12f683a2fc8e3e9fa56248</gtr:id><gtr:otherNames>Lachmann HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1478-6354</gtr:issn><gtr:outcomeId>CBE0F1F9E85</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A87AF110-CCDE-4D93-AF4C-A7A28428B9A9</gtr:id><gtr:title>Lack of effect of a single injection of human C-reactive protein on murine lupus or nephrotoxic nephritis.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/883d27e3755d90f0c9c6769873126cf5"><gtr:id>883d27e3755d90f0c9c6769873126cf5</gtr:id><gtr:otherNames>Carlucci F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>B89F8B88459</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>361644DE-1F18-4748-B52A-A5628F0FA981</gtr:id><gtr:title>Targeted treatment for amyloidosis.</gtr:title><gtr:parentPublicationTitle>The Israel Medical Association journal : IMAJ</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34527e5666b47e89e1bd770e03e887a6"><gtr:id>34527e5666b47e89e1bd770e03e887a6</gtr:id><gtr:otherNames>Pepys-Vered ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>545a3f83ad1307.02300204</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F82A77C3-2C65-4DE5-A51D-58FA41D584B7</gtr:id><gtr:title>Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a081056a7eb631885f825365a878d8c0"><gtr:id>a081056a7eb631885f825365a878d8c0</gtr:id><gtr:otherNames>Kastritis E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>AGjudY5Vai3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5190871-CCF1-4B05-B2E8-16AA0E6289FE</gtr:id><gtr:title>Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4310a9c0814170650d1e0146a62475ed"><gtr:id>4310a9c0814170650d1e0146a62475ed</gtr:id><gtr:otherNames>Hasserjian RP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>DF7185D171D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5710A10B-3016-42FE-9AFE-38DE648D9DBA</gtr:id><gtr:title>Renal amyloidosis in intravenous drug users.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e3975bd96bbef361c1dbf7454d49f63"><gtr:id>9e3975bd96bbef361c1dbf7454d49f63</gtr:id><gtr:otherNames>Connolly JO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>14C0FFBEDFD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D86DE0D-36CB-435A-A892-0EF436FA0F1A</gtr:id><gtr:title>Outcomes of heart transplantation for cardiac amyloidosis: subanalysis of the Spanish registry for heart transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef4512f8fd1df086398fd3391a2a91f0"><gtr:id>ef4512f8fd1df086398fd3391a2a91f0</gtr:id><gtr:otherNames>Sattianayagam PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>847219CB5E1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBFF9AD7-34F5-46AC-B68D-89B5C160D762</gtr:id><gtr:title>Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/824201aa8ac562c28c881c48d3331010"><gtr:id>824201aa8ac562c28c881c48d3331010</gtr:id><gtr:otherNames>Nedjai B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>8BDF39F1391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AEF693A-A70E-421E-A961-C575FAA6358B</gtr:id><gtr:title>Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers.</gtr:title><gtr:parentPublicationTitle>Circulation research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4046104e97e204569804a7efefb178f2"><gtr:id>4046104e97e204569804a7efefb178f2</gtr:id><gtr:otherNames>Lane T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-7330</gtr:issn><gtr:outcomeId>545a3f848cc306.80023458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A200C31B-60FF-4B97-8F00-1C6FC8CAD578</gtr:id><gtr:title>C-reactive protein and coronary heart disease: a critical review.</gtr:title><gtr:parentPublicationTitle>Journal of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf19195b6da69f15f5912aea3dcb019e"><gtr:id>cf19195b6da69f15f5912aea3dcb019e</gtr:id><gtr:otherNames>Casas JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0954-6820</gtr:issn><gtr:outcomeId>30477000A42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B81240D-FDDC-4635-B1FC-BB2C14FE8208</gtr:id><gtr:title>Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35ac4d52038241a41c9817f6d48f885d"><gtr:id>35ac4d52038241a41c9817f6d48f885d</gtr:id><gtr:otherNames>C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>pm_13505_25_21325005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2DD535D-CD6E-4E12-A3CF-B680C37CB176</gtr:id><gtr:title>Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb8299846a6d50c267ef12b2521ad7f"><gtr:id>2cb8299846a6d50c267ef12b2521ad7f</gtr:id><gtr:otherNames>Gillmore JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>AD5ACC31B44</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F24ED64C-8782-4E69-A99C-69A18ECE556B</gtr:id><gtr:title>Targeting C-reactive protein for the treatment of cardiovascular disease.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f38404ed7f6d03e85ca14c4790282d"><gtr:id>66f38404ed7f6d03e85ca14c4790282d</gtr:id><gtr:otherNames>Pepys MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>D9742A0AC68</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83465F3A-0046-40BC-BF82-814D47E5A2F1</gtr:id><gtr:title>A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe83a38923db5c26f6f6505c46e7ed91"><gtr:id>fe83a38923db5c26f6f6505c46e7ed91</gtr:id><gtr:otherNames>Marcoux J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>56d02af7ab97a0.04201860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45BFD887-6B6C-413F-B97F-3B7965EA54C5</gtr:id><gtr:title>Amyloidosis.</gtr:title><gtr:parentPublicationTitle>Annual review of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f38404ed7f6d03e85ca14c4790282d"><gtr:id>66f38404ed7f6d03e85ca14c4790282d</gtr:id><gtr:otherNames>Pepys MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0066-4219</gtr:issn><gtr:outcomeId>709492C0181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70C3BF8D-A7C5-4054-8F1B-EE9FB4FA6083</gtr:id><gtr:title>Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a72f4ea6fa9621190c36565639917ef8"><gtr:id>a72f4ea6fa9621190c36565639917ef8</gtr:id><gtr:otherNames>Hamour IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>CED56C9BCA0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC1DB7E8-49F5-4B7C-AD40-72234AF18420</gtr:id><gtr:title>Systemic diseases: from amyloidosis to cryoglobulinemia.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b3a7b2e371cfb5d30b6a520ac6668a3"><gtr:id>2b3a7b2e371cfb5d30b6a520ac6668a3</gtr:id><gtr:otherNames>Gr?nfeld JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>N9FiAnysacV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52BA7B27-86C3-44D8-A656-E415266A5D55</gtr:id><gtr:title>C-reactive protein and coronary disease: is there a causal link?</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77c6a665681719baba455e4c01af85be"><gtr:id>77c6a665681719baba455e4c01af85be</gtr:id><gtr:otherNames>Danesh J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>7F849F57BB2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1608AE-D162-42A2-986A-9A608F800A34</gtr:id><gtr:title>Amyloidosis and the lung.</gtr:title><gtr:parentPublicationTitle>Chronic respiratory disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce7d0fb8f12f683a2fc8e3e9fa56248"><gtr:id>1ce7d0fb8f12f683a2fc8e3e9fa56248</gtr:id><gtr:otherNames>Lachmann HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1479-9723</gtr:issn><gtr:outcomeId>64F0CD48A9D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E78F771-D0CB-4A6C-B5C2-474FC5EF385D</gtr:id><gtr:title>Solid organ transplantation in AL amyloidosis.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef4512f8fd1df086398fd3391a2a91f0"><gtr:id>ef4512f8fd1df086398fd3391a2a91f0</gtr:id><gtr:otherNames>Sattianayagam PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>GSDvsZ4JA7r</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1E80EE9-7690-4444-A92E-43EA0788C542</gtr:id><gtr:title>Images in cardiovascular medicine. Intermittent loss of second heart sound.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85f7ffe2107759190a3e46d0f44f14a7"><gtr:id>85f7ffe2107759190a3e46d0f44f14a7</gtr:id><gtr:otherNames>Joshi J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>E124CA5CEBC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>525EBBBB-EFEC-4DE8-A18B-65AFFE3737C4</gtr:id><gtr:title>Beta-edge interactions in a pentadecameric human antibody V kappa domain.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/413eff2f4a5d4faf73a5ac9ea92f6a17"><gtr:id>413eff2f4a5d4faf73a5ac9ea92f6a17</gtr:id><gtr:otherNames>James LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>1C1C4B730D0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91CEE451-3B78-410A-92B2-567B9FB7D86E</gtr:id><gtr:title>Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56a12cb17317ac844dd3c546061d293c"><gtr:id>56a12cb17317ac844dd3c546061d293c</gtr:id><gtr:otherNames>Mangione PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>545a3f84603702.79258044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B42199F0-CDB3-4B83-A4CE-A5AAC4CADD90</gtr:id><gtr:title>Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc39bd1ec01b3f71dbde14b5bec16710"><gtr:id>bc39bd1ec01b3f71dbde14b5bec16710</gtr:id><gtr:otherNames>Kolstoe SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>545a3f8385f715.17086277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58FB6D67-24A9-4D59-A085-A136D9B4CF43</gtr:id><gtr:title>Multinucleated Giant Cells Are Specialized for Complement-Mediated Phagocytosis and Large Target Destruction.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c907c347b5f247a0a72d725712e6e322"><gtr:id>c907c347b5f247a0a72d725712e6e322</gtr:id><gtr:otherNames>Milde R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d02b30a52551.48925882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39AF5885-7DF7-4837-B87A-01E5F49FB060</gtr:id><gtr:title>Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular A? amyloid deposits in vivo.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bb7845d1c212063fae2a57e455a4840"><gtr:id>0bb7845d1c212063fae2a57e455a4840</gtr:id><gtr:otherNames>Al-Shawi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56d02d4b7cdb17.84367322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7291D8C-3B22-43CA-89A1-5B9F8FDF61E2</gtr:id><gtr:title>Hereditary amyloidosis with progressive peripheral neuropathy associated with apolipoprotein AI Gly26Arg: outcome of hepatorenal transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5a41a48adcf30cdf37382ef65d65853"><gtr:id>f5a41a48adcf30cdf37382ef65d65853</gtr:id><gtr:otherNames>Testro AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>D631058A13F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3ED7AF42-2ADC-4731-A7DB-B965C9F13274</gtr:id><gtr:title>Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2df4cb59d7e76cbdc9be11dd8e36a516"><gtr:id>2df4cb59d7e76cbdc9be11dd8e36a516</gtr:id><gtr:otherNames>Bodin K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>mNqo7qBJTd6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0CA407D-0A1A-46B7-9338-16E07B6785D3</gtr:id><gtr:title>Characterisation and management of vitreous and nerve amyloid in familial amyloid polyneuropathy due to variant transthyretin, Phe33Val.</gtr:title><gtr:parentPublicationTitle>The British journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a1f5b1d519c3b1cba4cde0bdfff45e5"><gtr:id>4a1f5b1d519c3b1cba4cde0bdfff45e5</gtr:id><gtr:otherNames>Gregory ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1161</gtr:issn><gtr:outcomeId>9BBA081A9DA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FD102BE-7843-428A-ADD9-D618B8466D90</gtr:id><gtr:title>Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84f4de2b94fa8f7a21f7bcf83bff576b"><gtr:id>84f4de2b94fa8f7a21f7bcf83bff576b</gtr:id><gtr:otherNames>Goldbach-Mansky R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>1E45172AAA4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9307232-D44F-404A-AD91-94383C23439C</gtr:id><gtr:title>Serum amyloid P and fibrosis in systemic sclerosis: comment on the article by Tennent et al.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76b243250c2501af625ef29dcf716230"><gtr:id>76b243250c2501af625ef29dcf716230</gtr:id><gtr:otherNames>Pilling D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>E28B08A5CE1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FC2B16E-7BBC-4E81-8B04-81343178D4CA</gtr:id><gtr:title>Science and serendipity.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f38404ed7f6d03e85ca14c4790282d"><gtr:id>66f38404ed7f6d03e85ca14c4790282d</gtr:id><gtr:otherNames>Pepys MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>8BA851E7F4A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>487EBC30-A2A3-4D12-8129-B8B5ED8B295C</gtr:id><gtr:title>Outcome of autologous stem cell transplantation for AL amyloidosis in the UK.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbeadc30794a5e9ee34583712a1b3d5b"><gtr:id>cbeadc30794a5e9ee34583712a1b3d5b</gtr:id><gtr:otherNames>Goodman HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>6D341405FAD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7B0AAC9-45F6-4FB3-AD66-384E0926339C</gtr:id><gtr:title>Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component.</gtr:title><gtr:parentPublicationTitle>Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f38404ed7f6d03e85ca14c4790282d"><gtr:id>66f38404ed7f6d03e85ca14c4790282d</gtr:id><gtr:otherNames>Pepys MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1350-6129</gtr:issn><gtr:outcomeId>58b5a310340037.44238052</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC55ADA2-EF67-42C8-85A8-0A78FEA6EA69</gtr:id><gtr:title>Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Cardiovascular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbf0725706c062574f880feafb8d0c4e"><gtr:id>dbf0725706c062574f880feafb8d0c4e</gtr:id><gtr:otherNames>Wechalekar AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1743-4297</gtr:issn><gtr:outcomeId>E2F073499C6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4978F4AF-D5E0-4742-8689-9576FE8861DC</gtr:id><gtr:title>Biochemical basis of the amyloid diseases.</gtr:title><gtr:parentPublicationTitle>British journal of hospital medicine (London, England : 2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4097327de79c7f9118988ab900bbe699"><gtr:id>4097327de79c7f9118988ab900bbe699</gtr:id><gtr:otherNames>Gibbs SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1750-8460</gtr:issn><gtr:outcomeId>mqd9BB8SUJN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>654EBE71-9B3C-4C3F-8250-B38558E6E377</gtr:id><gtr:title>Normal circulating serum amyloid P component concentration in systemic sclerosis.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/458ba87b7b0d20eff58e31fac88e2544"><gtr:id>458ba87b7b0d20eff58e31fac88e2544</gtr:id><gtr:otherNames>Tennent GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>8B6F7E05299</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4379DDF1-6981-47D1-AF3B-09CEC2ACCFE8</gtr:id><gtr:title>Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV-infected patient.</gtr:title><gtr:parentPublicationTitle>The American journal of the medical sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2836a56740fd01e18d276f9ed747b94d"><gtr:id>2836a56740fd01e18d276f9ed747b94d</gtr:id><gtr:otherNames>Chan-Tack KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0002-9629</gtr:issn><gtr:outcomeId>0E537179C38</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCCAC597-AF65-46FF-91C4-A412D0567823</gtr:id><gtr:title>Protection of human podocytes from shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P component.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/879af31394c110c1413873d8fd8f1e48"><gtr:id>879af31394c110c1413873d8fd8f1e48</gtr:id><gtr:otherNames>Dettmar AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>545a3f840e6294.28002488</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>690DA894-1D84-4074-80FF-E6B5E123B5CA</gtr:id><gtr:title>Systemic AL (light-chain) amyloidosis and the gastrointestinal tract.</gtr:title><gtr:parentPublicationTitle>Scandinavian journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bd05222092c7f71254b89a661b2f6b9"><gtr:id>0bd05222092c7f71254b89a661b2f6b9</gtr:id><gtr:otherNames>Sattianayagam P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0036-5521</gtr:issn><gtr:outcomeId>FA81CA230DC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD2C18FE-1442-499F-B40F-0280A2792FC3</gtr:id><gtr:title>Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a1274c922796e91d5bd1d7ce6b8501d"><gtr:id>9a1274c922796e91d5bd1d7ce6b8501d</gtr:id><gtr:otherNames>Armstrong GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>9D7086CEDB1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13E05745-F101-4A8E-8569-0DFFE19CE1F2</gtr:id><gtr:title>The emerging role of interleukin-1? in autoinflammatory diseases.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce7d0fb8f12f683a2fc8e3e9fa56248"><gtr:id>1ce7d0fb8f12f683a2fc8e3e9fa56248</gtr:id><gtr:otherNames>Lachmann HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>TGtB8yYunWW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CE9003B-4986-48C9-A21E-1E5816DE0AA3</gtr:id><gtr:title>Transgenic human CRP is not pro-atherogenic, pro-atherothrombotic or pro-inflammatory in apoE-/- mice.</gtr:title><gtr:parentPublicationTitle>Atherosclerosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/458ba87b7b0d20eff58e31fac88e2544"><gtr:id>458ba87b7b0d20eff58e31fac88e2544</gtr:id><gtr:otherNames>Tennent GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9150</gtr:issn><gtr:outcomeId>A81CDD74A53</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26E7277F-075F-4AB7-95F6-6780DF80C5D4</gtr:id><gtr:title>Drug Insight: emerging therapies for amyloidosis.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb8299846a6d50c267ef12b2521ad7f"><gtr:id>2cb8299846a6d50c267ef12b2521ad7f</gtr:id><gtr:otherNames>Gillmore JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1745-8323</gtr:issn><gtr:outcomeId>AEBDE6EBC81</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04107DDF-2E71-4DEC-832B-1414D7A90C9C</gtr:id><gtr:title>Perspectives in treatment of AL amyloidosis.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbf0725706c062574f880feafb8d0c4e"><gtr:id>dbf0725706c062574f880feafb8d0c4e</gtr:id><gtr:otherNames>Wechalekar AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>8C6A448E3E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E2D7F33-F558-48D2-A9F4-37DCA0990593</gtr:id><gtr:title>Natural history and outcome in systemic AA amyloidosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce7d0fb8f12f683a2fc8e3e9fa56248"><gtr:id>1ce7d0fb8f12f683a2fc8e3e9fa56248</gtr:id><gtr:otherNames>Lachmann HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>9F5FFA361D7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F221EFFA-C7D5-4F41-BEA4-7273FBC9E49F</gtr:id><gtr:title>A molecular correlate of clinicopathology in transthyretin amyloidosis.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f38404ed7f6d03e85ca14c4790282d"><gtr:id>66f38404ed7f6d03e85ca14c4790282d</gtr:id><gtr:otherNames>Pepys MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>1D96761F16D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B852D514-F764-4ED1-90E5-396923B8EC28</gtr:id><gtr:title>Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ce7d0fb8f12f683a2fc8e3e9fa56248"><gtr:id>1ce7d0fb8f12f683a2fc8e3e9fa56248</gtr:id><gtr:otherNames>Lachmann HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>C86538E8926</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>269E7DA9-6F12-4440-BD39-0BAAC69AAD9C</gtr:id><gtr:title>From scleredema to AL amyloidosis: disease progression or coincidence? Review of the literature.</gtr:title><gtr:parentPublicationTitle>Clinical rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4822869955ca9cd3a6c4e292dec2ba36"><gtr:id>4822869955ca9cd3a6c4e292dec2ba36</gtr:id><gtr:otherNames>Dziadzio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0770-3198</gtr:issn><gtr:outcomeId>45D4CC0D8EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE96ABAC-66C3-43AB-A1A4-9689D943B2EE</gtr:id><gtr:title>Amyloid and the GI tract.</gtr:title><gtr:parentPublicationTitle>Expert review of gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0bd05222092c7f71254b89a661b2f6b9"><gtr:id>0bd05222092c7f71254b89a661b2f6b9</gtr:id><gtr:otherNames>Sattianayagam P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1747-4124</gtr:issn><gtr:outcomeId>571535D2E53</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A71BCF82-D828-43D1-913C-C09049E81BA9</gtr:id><gtr:title>C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00954130f581451305ebfe461866731f"><gtr:id>00954130f581451305ebfe461866731f</gtr:id><gtr:otherNames>Emerging Risk Factors Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>F9PpmcRb6nn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06BE5232-9A46-4AE0-B870-83E701A2E6B1</gtr:id><gtr:title>Is leptin an important physiological regulator of CRP?</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a6d40f6e987ca561a860bb1c9620ba0"><gtr:id>3a6d40f6e987ca561a860bb1c9620ba0</gtr:id><gtr:otherNames>Hutchinson WL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>CD8D3C439BB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDD40849-83D3-4801-8997-EFC148D29F73</gtr:id><gtr:title>C-reactive protein and cardiovascular disease: weighing the evidence.</gtr:title><gtr:parentPublicationTitle>Current atherosclerosis reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5fa914fceb07c037026560416420c1a6"><gtr:id>5fa914fceb07c037026560416420c1a6</gtr:id><gtr:otherNames>Lowe GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1523-3804</gtr:issn><gtr:outcomeId>A9169BA7C17</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>048EF0BB-5504-4FAE-9306-62811127B00D</gtr:id><gtr:title>Eprodisate for the treatment of renal disease in AA amyloidosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f559afdf6cc9498788b1f6950f3b7bc"><gtr:id>4f559afdf6cc9498788b1f6950f3b7bc</gtr:id><gtr:otherNames>Dember LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>862667E14D9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D60EF80-B5A5-4EB3-AE0C-7FB401FC84E2</gtr:id><gtr:title>Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f38404ed7f6d03e85ca14c4790282d"><gtr:id>66f38404ed7f6d03e85ca14c4790282d</gtr:id><gtr:otherNames>Pepys MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>pm_13505_25_22867744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8A1DAE1-AA56-4866-96F0-34407262BFEC</gtr:id><gtr:title>Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbf0725706c062574f880feafb8d0c4e"><gtr:id>dbf0725706c062574f880feafb8d0c4e</gtr:id><gtr:otherNames>Wechalekar AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>0A8B52C1CCB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A2495AF0-540B-4ABB-B811-8653C15A72B3</gtr:id><gtr:title>A novel amyloidogenic transthyretin variant, Gly53Ala, associated with intermittent headaches and ataxia.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4ee0789f9f5930d9f44f57ed3ac8e64"><gtr:id>e4ee0789f9f5930d9f44f57ed3ac8e64</gtr:id><gtr:otherNames>Douglass C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>13A257EA2F6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A7590B1-2B2F-4884-9058-4F598A9FF528</gtr:id><gtr:title>Trapping of palindromic ligands within native transthyretin prevents amyloid formation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc39bd1ec01b3f71dbde14b5bec16710"><gtr:id>bc39bd1ec01b3f71dbde14b5bec16710</gtr:id><gtr:otherNames>Kolstoe SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>nypSGE7u33s</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G7900510</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>20</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>